



Analgesic efficacy and safety of erector spinae plane block versus serratus anterior plane block in breast surgery—a meta-analysis and systematic review of randomized controlled trials

Samiullah Shaikh^{1*}, Umm E Salma Shabbar Banatwala², Paranshi Desai³, Muhammad Arham Khan², Rimsha Bint-e-Hina², Sidra Samad¹, Muhammad Hamza Sikandari⁴, Ali Nawaz⁵, Rana Ijaz⁶, Shayan Asmat⁵, Abeer Fatima⁷, Harim Mirza², Noor Mahal Azam⁸, Qurat Ul Ain Muhammad⁸, Satesh Kumar⁴ and Mahima Khatri²

Abstract

Background Mastectomy and breast-conserving surgery are key interventions for breast cancer, a leading cause of cancer-related mortality in women. Many undergoing breast surgery experience postoperative pain compromising their functionality and quality of life. While multiple pain management strategies are available, evidence comparing the erector spinae (ESPB) and serratus anterior plane blocks (SAPB) for improving post-surgical pain management in breast cancer surgery patients is limited. Therefore, we investigated the efficacy and safety of these two regional anesthesia techniques.

Methods After PROSPERO registration, we systematically searched PubMed, Google Scholar, and Cochrane Library until May 2024. Risk ratios (RR) were calculated for dichotomous outcomes and standard mean differences (SMD) or mean differences (MD) were computed for continuous data. RevMan Review Manager 5.4.1 was used for the data analysis and generation of forest plots as well as funnel plots. The Cochrane Risk of Bias tool 2.0 (18) and Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) guidelines were used to appraise and evaluate the evidence (19).

Results A total of 9 randomized control trials enrolling 550 patients were included. Static pain scores at 0, 6, 8, 12, and 24 h after surgery, dynamic pain scores computed at 0, 8, 12, and 24 h after surgery and area under the curve (AUC) static pain score at all time points between 0 and 24 h (SMD (HKSJ 95% CI) - 0.27 [-0.99, 0.45]) did not significantly vary with either plane block. Postoperative morphine consumption in the first 24 h and the number of patients requesting analgesia were significantly greater in those receiving SAPB [MD: -1.41 (95% C.I. -2.70, -0.13), p = 0.03] and [RR: 1.28 (95% C.I. 1.00, 1.63), p = 0.05], respectively. The time to first postoperative analgesic use was significantly

*Correspondence: Samiullah Shaikh sami.shaikh581@gmail.com Full list of author information is available at the end of the article



© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/

greater among those administered ESPB [MD: 1.55 h, (95% C.I. 1.02, 2.09), p < 0.01]. Patient satisfaction scores and the incidence of nausea and vomiting were similar across both groups.

Conclusions While pain scores with either block are comparable, ESPB reduces postoperative morphine consumption and may be the favorable option in breast cancer patients undergoing surgery.

Keywords ESPB, SAPB, Postoperative pain, Regional anesthesia, Breast cancer surgery

Introduction

Mastectomy and breast-conserving surgery are pivotal in the management of breast cancer, a disease that ranks among the leading causes of cancer-related mortality in women globally [1, 2]. Projections indicate a 31% surge in breast cancer incidence by the year 2040 compared to 2020 Figs. [3]. A significant proportion of women, ranging from 25 to 80%, grapple with post-surgical pain following breast cancer surgery, leading to compromised functionality and diminished quality of life [4–6]. Such findings underscore a pressing imperative for better pain management strategies.

Direct tissue trauma, compounded by inflammatory processes at the surgical site, serves as a primary instigator of acute postoperative pain [7]. Conversely, individuals undergoing breast cancer surgery may also contend with chronic pain, encompassing phenomena such as phantom breast pain, intercostobrachial neuralgia, and pain stemming from nerve injury or neuroma development [8]. While consensus on optimal pain management strategies remains elusive, expert counsel advocates for preemptive oral analgesia, judicious use of nerve blocks (pre-, intra-, or postoperative as appropriate), and prudent restriction of opioid medications [9]. Notable nerve block techniques include the thoracic paravertebral, erector spinae, pectoralis, and serratus anterior plane blocks. While the thoracic epidural and paravertebral blocks are not appropriate for minimally invasive surgery due to associated complications, ultrasound-guided thoracic blocks such as the pectoral nerve, serratus anterior plane, and erector spinae plane blocks are gaining traction due to their efficacy and safety profiles [10].

The serratus anterior plane block (SAPB) selectively targets the lateral cutaneous branches of thoracic intercostal nerves, eliciting paresthesia across T2 to T9 dermatomes. Conversely, the erector spinae plane block (ESPB), a paraspinal fascial plane blockade, achieves a comprehensive sensory blockade by impeding the dorsal and ventral rami of thoracic spinal nerves. Its distinctive spread affords abdominal visceral analgesia as well, rendering it a promising option [11, 12]. Recently, ESPB has garnered more interest due to its use in various surgeries. Multiple meta-analyses published have investigated ESPB in providing postoperative pain relief in a multitude of procedures ranging from sternotomies, spinal surgeries, and laparoscopic abdominal procedures shedding light on its diversified use [13, 14, 15].

Although previous systematic reviews and metaanalyses have delved into comparing the ESPB with the pectoralis nerve block and paravertebral block [16], or the SAPB with the thoracic paravertebral block [17], a notable gap exists in evidence synthesis concerning the ESPB versus the SAPB. Given the proliferation of trials directly comparing the efficacy and safety profiles of these two plane blocks, consolidating this evidence is imperative to discern the superior option for breast surgeries. Thus, this systematic review and meta-analysis seeks to investigate and compare the analgesic efficacy and safety of the erector spinae plane block versus the serratus anterior plane block in the context of breast surgery.

Methods

This systematic review and meta-analysis was conducted following the preferred reporting items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [18]. The protocol for this review was registered in the PROS-PERO (International Prospective Register for Systematic Reviews) database with ID CRD42024507382.

Eligibility criteria

Randomized controlled trials (RCTs) that met the following criteria were included: (1) studies assessing the use of erector spinae plane block (ESPB) as the intervention and serratus anterior plane block (SAPB) as the comparator, (2) patients undergoing breast cancer surgery (radical mastectomy or modified radical mastectomy), (3) assessing outcomes related to analgesic efficacy and safety, (4) area under the curve (AUC) pain score at static between 0 and 24 h, (5) postoperative morphine or morphine equivalent (mg) consumption in first 24 h postoperatively, and (6) studies providing full-text access, either in English or any other language. Moreover, articles that did not provide the data necessary for calculating a mean difference or standard mean difference (MD or SMD) and a 95% confidence interval (CI) were excluded.

Literature search strategy

A systematic literature search was conducted on electronic databases and included PubMed, Google Scholar, and Cochrane Library from inception through May 2024. The keywords used to retrieve all pertinent publications were: "erector spinae plane block," "serratus anterior plane block," "breast surgery," "postoperative analgesia," and "pain management." The detailed search technique is provided in the online supplementary appendix A. Furthermore, the bibliography of potentially eligible articles was examined for relevant studies.

Study selection process

Two independent reviewers [P.D. and S.S.] screened titles and abstracts of retrieved studies, and full texts of potentially eligible studies were assessed for final inclusion. Zotero was used to store references and remove any duplicate studies. Discrepancies were resolved through discussion or consultation with a third reviewer [U.S.S.B].

Data extraction

Data extraction forms were created on Google Sheets by the data extraction team [S.S and R.B.H]. Each team member independently extracted data. Extracted data were verified by a third reviewer [N.M.A]. Relevant data extracted from included studies are as follows: (1) study characteristics: first author name, publication year, and study design; (2) patient demographics: total number of participants, mean age, gender, and BMI; (3) intervention details: type of surgery, type of block performed (ESPB or SAPB), technique used, and analgesic regimen used; (4) outcome measures: primary outcomes included AUC postoperative pain scores between 0 and 24 h and postoperative opioid consumption in first 24 h, and secondary outcomes included postoperative static and dynamic pain scores at 0, 6, 8, 12, and 24 h, time to first postoperative analgesic request, patient satisfaction score, and incidence of adverse events (e.g., nausea, vomiting). For continuous outcome data, mean and standard deviation were extracted. Standardized statistical conversions were made if the data were reported as median and interquartile range (IQR) and conversion was done on online calculator [19, 20]. Dichotomous data were extracted in events/total format. Graphical data were extracted using the Plot digitizer online application [21].

Primary and secondary outcomes

The co-primary outcomes evaluated in this systematic review and meta-analysis were the area under the curve of postoperative pain scores static between 0 and 24 h (AUC pain score at static between 0 and 24 h) and postoperative oral morphine or morphine equivalent consumption in 24 h. The secondary outcomes were postoperative pain scores static at 0, 6, 8, 12, and 24 h and dynamic at 0, 8, 12, and 24 h, time to the first dose of postoperative opioids, number of patients requested opioids postoperatively, patient satisfaction score, and incidence of vomiting and nausea.

Quality assessment and risk of bias

To evaluate the methodological quality of the included RCTs, the Cochrane Collaboration Risk-of-Bias tool 2.0 [22] was employed. This tool comprises five domains, namely, bias arising from randomization, bias due to deviations from planned interventions, bias due to missing outcome data, bias in the measurement of the outcome, and bias of selective reporting. Two independent reviewers [R.I and A.N] assessed each trial's methodology and assigned a risk of bias rating as low, unclear, or high based on predetermined criteria. Any discrepancies between the reviewers were resolved through reevaluation by a third reviewer [S.S.].

For the assessment of the overall strength of evidence, the GRADE guidelines [23] were utilized. These guidelines classify the strength of evidence into four levels: high-quality ($\oplus \oplus \oplus \oplus$), moderate-quality ($\oplus \oplus \oplus \ominus$), low-quality ($\oplus \oplus \oplus \ominus$), and very-low-quality ($\oplus \oplus \ominus \ominus$) evidence.

Measurement of outcomes

Postoperative pain scores were assessed both at rest (static) and during movement (dynamic) at 0, 6, 8, 12, and 24 h after the surgery. The pain score data were transformed into an equivalent score on a 0–10-cm visual analog scale (VAS), with 0 cm corresponding to no pain and 10 cm corresponding to the worst experienced pain. Additionally, the doses of various postoperative opioids consumed within 24 h were converted into equivalent doses of oral morphine in milligrams using a standardized converter [24]. All time-to-event data was converted into hours for uniformity and ease of comparison.

AUC analysis

AUC of rest pain scores was calculated for each trial between 0 and 24 h time interval using the trapezoid method [25]. Pooling the trials was then done using the HKSJ method for random effects [26].

Interpretation

We looked at our main results to see if they were important for patients in terms of minimal clinically important difference (MCID) [27]. For the "postoperative pain scores (static and dynamic)," we considered it meaningful if the average pain score [28] on the visual analog scale (VAS) decreased by more than 1.1 cm. For the "24-h postoperative oral morphine (mg) equivalent consumption," we considered it significant [28] if the average amount of morphine used was reduced by more than 30 mg.

Statistical analysis

For the meta-analysis, Review Manager 5.4.1 software was utilized to generate funnel and forest plots. The following methods were employed for calculating effect sizes and conducting statistical tests: The generic-inverse variance method with a random-effects model was employed to calculate the standard mean difference (SMD) for continuous variables related to postoperative pain scores due to the diversity of scales used and mean difference (MD) for the rest of the continuous variables along with the corresponding 95% confidence interval (CI). For dichotomous variables, the Mantel–Haenszel method with a random-effects model was utilized to calculate the risk ratio (RR). The threshold for statistical significance was set at p < 0.05.

The results of the pooled studies were visually represented using forest plots, which provide a graphical display of the effect sizes and their confidence intervals. Funnel plots were constructed to assess publication bias of the outcomes via visual inspection. The degree of inconsistency among the included studies was assessed using Higgins' I^2 test, which quantifies the percentage of total variation across studies due to heterogeneity rather than chance. The degree of heterogeneity was categorized as follows: Low heterogeneity: $I^2 < 25\%$, moderate heterogeneity: $I^2 > 75\%$. Moderate and high levels of heterogeneity prompted exploration into the potential causes of heterogeneity as outlined in the literature [29].

Methods to explore causes of heterogeneity

To understand the causes of differences in results, we employed following analytical approaches. Firstly, we conducted a sensitivity analysis where we sequentially excluded studies based on (1) the usage or non-usage of alprazolam and midazolam as adjuncts on the day of surgery and (2) the use of any local anesthetic (LA) other than the most commonly used LA, i.e., bupivacaine. This analysis helped us assess how the results changed when specific studies were removed from the analysis, providing insights into the reliability of our findings. Additionally, we performed a subgroup analysis for our two primary outcomes by dividing the studies into two subgroups, i.e., "Bupivacaine vs others" before and after excluding the studies sequentially. The usage of benzodiazepine as adjuncts on the day of surgery and LA other than bupivacaine were identified as potential sources of high heterogeneity.

Results

Study selection

An extensive literature search yielded a total of 5192 results. Considering the study eligibility criteria, 94 articles were subjected to screening after reviewing the titles and abstract. The remaining records were scrutinized based on full-text, and after ruling out 85 studies due to ineligible study design and comparison group, 9 RCTs [30–38] were included in this meta-analysis (Fig. 1).

Study and patient characteristics

A total of nine RCTs were included in this meta-analysis. These studies were conducted in various countries, such as Egypt, China, and India, from 2019 to 2024. The included number of patients was 550 as demonstrated by Table 1. The number of participants in the studies ranged from 40 to 100. The population assessed in a number of these studies is females undergoing radical mastectomy [37] and modified radical mastectomy (MRM) [30, 31, 33–37] (Table 1). Four studies [32–35] used 0.25%, 0.375 and 0.5% ropivacaine, four studies [31, 36–38] used 0.25% bupivacaine and one study [30] used 2% articaine. The baseline characteristics of studies and anesthesia are specified in Tables 1 and 2.

Risk of bias

All nine studies [30–38] adequately described the random sequence generation methods and reported using allocation concealment to reduce bias. Eight studies showed low risk for detection bias [30–36, 38] and performance bias [30–33, 35–38]. Seven studies [30, 32, 34–38] explicitly reported low risk for attrition bias. Six studies [30, 33–37] were low risk for reporting bias (Fig. 2).

Outcomes

Outcomes are represented in a tabulated form in online supplementary appendix B.

Primary outcomes

AUC pain score at static between 0 and 24 h

Seven studies [30, 31, 34–38] inclusive of 390 patients (ESPB: 195, SAPB: 195) reported rest pain scores at all time points between 0 and 24 h. The pooled analysis showed that AUC pain score in patients receiving ESPB and SAPB did not significantly vary (SMD (HKSJ 95% CI)–0.27 [-0.99, 0.45], p=0.46, $I^2=91\%$) (Fig. 3a). None of the SMDs reached the threshold of minimal clinically important difference (MCID). This analysis was characterized by substantial inconsistency ($I^2=91\%$), but our results were robust to sensitivity analysis; the exclusion of studies [34, 37] on the basis of use of alprazolam in the morning on the day




Fig. 1 PRISMA flowchart. PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses

of surgery that synergistically enhances postoperative analgesic effect reduced the heterogeneity to 71% (SMD (HKSJ 95% CI)=0.25 (-0.20 to 0.71) (p=0.27, I^2 =71%) (Fig. 3b). Visually, the funnel plot appeared symmetrical (online supplemental appendix C), indicating an absence of publication bias. Overall, the GRADE strength of evidence was moderate (Table 2).

Postoperative morphine or morphine equivalent (mg) consumption in the first 24 h postoperatively

Nine studies [30-38] inclusive of 550 (ESPB: 275, SAPB: 275) reported morphine or morphine equivalent (mg) consumption in the first 24 h postoperatively. The pooled analysis of equivalent doses of oral morphine in milligrams revealed that the dose of morphine consumption was lower in the ESPB group as compared to the SAPB group and the results were statistically significant (MD = -1.41 [-2.7, -0.13], p < 0.03, $I^2 = 94\%$) (Fig. 4a). Although statistically significant, the results were clinically insignificant based on the set criteria. This analysis was characterized by substantial inconsistency, but sensitivity analysis by excluding the study [38] based on the lowest time taken for surgery and unspecified surgery type failed to resolve inconsistency for this outcome ($I^2 = 86\%$). Furthermore, subgroup analysis was performed by dividing the studies based on LA modality, i.e., "Bupivacaine" and "Others" (Fig. 4b). There was substantial inconsistency, for which sensitivity analysis was done. On sensitivity analysis, the exclusion of the study [37] based on the use of alprazolam on the day of surgery that synergistically enhances postoperative analgesic strength reduced heterogeneity in the subgroup "Bupivacaine" to 68% (Fig. 4c). There was a symmetrical appearance

Author, year	Total number Number of of patients patients in e group	Number patients group	Number of patients in each group	Age		Gender (M/F)	- (M/F)	BMI		Physical status ASA I/II/III	tatus	Type of surgery
		ESPB	SAPB	ESPB	SAPB	ESPB	SAPB	ESPB	SAPB	ESPB	SAPB	
Eldemrdash 2019 [30]	50	25	25	55 (2.9)	50.2 (7.8)	ш	 ш	26.2 (1.8)	23.5 (3.2)	14/11	12/13	MRM
Wang 2019 [32]	100	50	50	52 (7)	49 (7)	ш	ш	N/A	N/A	N/A	N/A	Radical mastectomy
Elsabeeny 2020 [31]	50	25	25	51.80 (9.07)	52.44 (8.70)	ш	ш	28.05 (2.4)	27.30 (2.5)	N/A	N/A	MRM
Shrivastava 2021 [38]	50	25	25	45.41 (11.22)	44.40 (10.45)	ш	ш	160 (30)	161 (20)	N/A	N/A	Unspecified
Jiang 2021 [<mark>33</mark>]	60	30	30	54.73 (13.60)	52.10 (11.50)	ш	ш	23.40 (3.0)	23.52 (3.1)	13/17	18/12	MRM
Sagar 2022 [<mark>37</mark>]	40	20	20	53.95 (4.796)	53.90 (4.064)	ш	ш	25.53 (2.5)	24.89 (3.21)	N/A	N/A	MRM
Ahuja 2022 [35]	80	40	40	49.6 (11.5)	45.9 (10.0)	ш	ш	26.5 (4.4)	24.89 (3.6)	15/24/1	23/17/0	MRM
Nyima 2023 [34]	80	40	40	50.38 (11.24)	53.08 (14.18)	ш	ш	N/A	N/A	20/20	18/22	MRM
Bedewy 2024 [36]	40	20	20	47 (7.54)	45.65 (5.40)	ш	ш	N/A	N/A	N/A	N/A	MRM
ESPB erector spinae plane block, SAPB serratus anterior plane block, N/A not applicable, BMI body mass index, ASA American Standards Association	olock, SAPB serratus à	anterior pla	ne block, <i>N</i> //	A not applicable, B/	<i>WI</i> body mass index	, ASA Ameri	ican Standar	ds Association				

E
Å
led
pn
finc
ofi
S
isti
cter
ğ
cha
ě
<u>ار</u>
Bas
~
ø
ab
-

Author/year	Preincisional analgesia and anti-emetics	Block timing	ESPB local anesthetic bolus	SAPB local anesthetic bolus Localization	Localization	Supplemental and postoperative analgesia
Eldemrdash 2019 [30]	One gram of paracetamol was administered IV after induc- tion of anesthesia	Preoperative after (GA)	20 ml of 2% articaine	20 ml of 2% articaine	USG	One gram paracetamol was administered IV every 8 h
Wang 2019 [32]	1 g/kg dexmedetomidine was pumped (the pump was completed within 10 min)	Preoperative before (GA)	20 ml of 0.375% ropivacaine	20 ml of 0.375% ropivacaine	nsg	When the VAS score was >4 points, 50 mg of flurbiprofen axetil was added for analgesia. If the VAS score was still > 4 points after 30 min, sufentanil 5 g was given for each rescue analgesia, the dosage and times of flurbiprofen axetil and sufentanil rescue were recorded
Elsabeeny 2020 [31]	Patients were pre-medicated with midazolam (2 mg IV) and metoclopramide 0.1 mg/kg	Preoperative after (GA)	25 ml of 0.25% bupivacaine	25 ml of 0.25% bupivacaine	USG	Ketorolac when the VAS score was <4
Shrivastava 2021 [38]	Intravenous ondansetron 4 mg and dexamethasone 8 mg	Preoperative after (GA)	25 ml of 0.25% bupivacaine	25 ml of 0.25% bupivacaine	USG	When VAS score was 2 3, intrave- nous diclofenac 75 mg was given. If VAS was still 2 3, tramadol 50 mg was given till VAS < 3
Jiang 2021 [33]	A M	Preoperative after (GA)	20 ml of 0.5% ropivacaine	20 ml of 0.5% ropivacaine	USG	Within 24 h after the operation, the patients received an intra- venous injection of tramadol 1-2 mg/kg for pain relief until the NRS pain score was <3, and again if the postoperative NRS was greater than 3 points, trama- was greater than 3 points, trama- dol $1-2$ mg/kg was administered int ravenously, and then the pain was evaluated after 30 min
Ahuja 2022 [35]	Intravenous dexamethasone (0.1 mg kg – 1) and paracetamol (15 mg kg – 1) were administered immediately after induction	Preoperative before (GA)	30 ml of 0.25% ropivacaine	30 ml of 0.25% ropivacaine	USG	Intravenous infusion of paraceta- mol of 15 mg kg-1 immediately after induction and repeated every 8 h for the first 24 h. On assessment, if NRS was 23 at rest or arm abduction, first rescue analgesia, intravenous diclofenac sodium (1.5 mg kg 1) was admin- istered; not repeated within 12 h of the first dose. Patients were reassessed after 30 min; if NRS 2 persisted, a second rescue analgesic intravenous trama- dol hydrochoide (1 mg kg 1)

Author/year	Preincisional analgesia and anti-emetics	Block timing	ESPB local anesthetic bolus	ESPB local anesthetic bolus SAPB local anesthetic bolus Localization Supplemental and postoperative anal	Localization	Supplemental and postoperative analgesia
Nyima 2021 [34]	Oral ranitidine 150 and 0.25 mg alprazolam at night before sur- gery and at 6AM on the day of surgery	Preoperative after (GA)	20 ml of 0.25% ropivacaine	20 ml of 0.25% ropivacaine	SS N	1 g of paracetamol was adminis- tered to patients in both the study groups in case the VAS score >4. Rescue analgesia with 1 g of paracetamol was administered to patients in both the study groups in case the VAS score >4
Sagar 2022 [37]	Ranitidine 150 mg, tablet metoclopramide 10 mg and alprazolam 0.25 mg peroral on the night before and the day of the scheduled surgery as premedication	Preoperative after (GA)	24 ml of 0.25% bupivacaine	24 ml of 0.25% bupivacaine	USG	If the NRS was >4, rescue analge- sics were administered. Trama- dol 1-2 mg kg-1 was given IV as a first-line drug. If the pain persisted, paracetamol 15 mg kg-1 was administered IV
Bedewy 2024 [36]	Intravenous dose of midazolam ranging from 0.01 to 0.02 mg/ kg, administered 30 min before the operation	Preoperative after (GA)	20 ml of 0.25% of bupivacaine	20 ml of 0.25% of bupivacaine 20 ml of 0.25% of bupivacaine USG	USG	IV morphine at 0.05 mg/kg/dose was administered when NRS score > 4

GA general anesthesia, ESPB erector spir dexamethsone, VAS visual analog scale

		-		Risk of bia	s domains		
		D1	D2	D3	D4	D5	Overall
	Eldemrdash 2019 [26]	+	+	+	+	+	+
	Wang 2019 [28]	+	+	+	+	-	-
	Elsabeeny 2020 [27]	+	+	-	+	-	-
	Shrivsatava 2021 [34]	+	+	+	+	-	-
Study	Jiang 2021 [29]	+	+	-	+	+	-
	Ahuja 2022 [31]	+	+	+	+	+	+
	Sagar 2022 [33]	+	+	+	-	+	-
	Nyima 2023 [30]	+	-	+	+	+	-
	Bedewy 2024 [32]	+	+	+	+	+	+
		D2: Bias due D3: Bias due D4: Bias in r	e to deviations to missing o measurement	of the outcom	d intervention ne.	•	ment Some concerns Low
266.06	smont for the included trial			e reported res	uit.		



a

	E	SPB			SAPB			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Eldemrdash 2019 [26]	85.383	95.652	25	122.25	131.73	25	14.4%	-0.32 [-0.87, 0.24]	2019	
Elsabeeny 2020 [27]	48.198	1.359	25	45.231	28.869	25	14.4%	0.14 [-0.41, 0.70]	2020	-
Shrivastava 2021 [34]	54	17.958	25	36	17.958	25	14.2%	0.99 [0.40, 1.58]	2021	
Ahuja 2022 [31]	6.87	22.62	40	8.46	13.92	40	14.9%	-0.08 [-0.52, 0.35]	2022	-
Sagar 2022 [33]	59.55	10.434	20	77.1	9.075	20	13.5%	-1.76 [-2.50, -1.02]	2022	
Bedewy 2023 [32]	115.0485	42.4356	20	89.1273	36.5715	20	14.0%	0.64 [0.00, 1.28]	2023	-
Nyima 2023 [30]	60.18	17.958	40	88.2	17.958	40	14.6%	-1.55 [-2.05, -1.04]	2023	
Total (95% CI)			195			195	100.0%	-0.27 [-0.99, 0.45]		-
Heterogeneity: Tau ² = 0.	85; Chi ² = 68	.40, df = 6	(P < 0.	00001); F	= 91%					
Test for overall effect: Z =	= 0.74 (P = 0	.46)								-4 -2 U 2 4 Favours [ESPB] Favours [SAPBI]

b

	E	SPB			SAPB			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Eldemrdash 2019 [26]	85.383	95.652	25	122.25	131.73	25	19.9%	-0.32 [-0.87, 0.24]	2019	
Elsabeeny 2020 [27]	48.198	1.359	25	45.231	28.869	25	20.0%	0.14 [-0.41, 0.70]	2020	
Shrivastava 2021 [34]	54	17.958	25	36	17.958	25	19.3%	0.99 [0.40, 1.58]	2021	
Ahuja 2022 [31]	6.87	22.62	40	8.46	13.92	40	22.5%	-0.08 [-0.52, 0.35]	2022	
Sagar 2022 [33]	59.55	10.434	20	77.1	9.075	20	0.0%	-1.76 [-2.50, -1.02]	2022	
Bedewy 2023 [32]	115.0485	42.4356	20	89.1273	36.5715	20	18.3%	0.64 [0.00, 1.28]	2023	
Nyima 2023 [30]	60.18	17.958	40	88.2	17.958	40	0.0%	-1.55 [-2.05, -1.04]	2023	
Total (95% CI)			135			135	100.0%	0.25 [-0.20, 0.71]		•
Heterogeneity: Tau ² = 0.	19; Chi ² = 13	.60, df = 4	(P = 0.	009); l ² = 7	71%				-	
Test for overall effect: Z =	= 1.10 (P = 0.	27)								-4 -2 U 2 4 Favours [ESPB] Favours [SAPBI]

Fig. 3 a Forest plot of AUC postoperative pain scores (static) between 0 and 24 h. The SMD estimates for each study are represented by squares, and the lines passing through them represent 95% CI. The diamond represents the overall pooled estimate. **b** Postoperative pain scores (static) at 24 h (forest plot of sensitivity analysis). SMD standard mean difference, CI confidence interval, IV inverse variance, SD standard deviation, ESPB erector spinae plane block, SAPB serratus anterior plane block

Outcomes	No. of participants (studies)	Publication bias	Mean difference or RR (95%CI)	Indirectness	Strength or certainty of the evidence	Inconsistency	Limitations
Post opera- tive morphine equivalent (mg) consumption in the first 24 h postoperatively	550 (9)	Not detected	MD-1.41(-27,-0.13)	Not detected	⊕⊕⊕⊖ Moderate	High test for inconsistency (but resolved on subgroup analysis) $(l^2 = 94\%)$	No serious limitations
AUC postopera- tive pain score at 0–24 h (static)	390 (7)	Not detected	SMD – 0.27 (– 0.99, 0.45)	Not detected	⊕⊕⊕⊖ Moderate	High test for inconsistency (resolved on SA) $(l^2 = 91\%)$	No serious limitations
Post operative pain scores (static) at 24 h	550 (9)	Publication bias strongly suspected	SMD – 0.13 (– 1, 0.74)	Not detected	⊕⊕⊕⊖ Moderate	High test for inconsistency $(l^2 = 95\%)$ (resolved on SA)	No serious limitations
Post operative pain scores (dynamic) at 24 h	240 (3)	Publication bias strongly suspected	SMD -0.1 (-1, 0.74)	Not detected	⊕⊕⊕⊖ Moderate	Low test for inconsistency $(l^2 = 0\%)$	No serious limitations
No. of patients requested anal- gesia in the first 24 h postopera- tively	260 (4)	Not detected	1.28 [1.00,1.63]	Not detected	⊕⊕⊕⊕ High	Low test for inconsistency $(l^2 = 0\%)$	No serious limitations
Time to first postoperative analgesia use (h)	360 (6)	Not detected	MD 1.55 (1.02, 2.09)	Not detected	⊕⊕⊕⊕ High	High test for inconsist- ency (/ ² =79%) (resolved on SA)	No serious limitations
Patient satisfac- tion score	140 (2)	Not detected	-0.33 [-0.66, -0.01]	Not detected	⊕⊕⊕⊕ High	Low test for inconsistency $(l^2 = 0\%)$	No serious limitations

Table 3 Evidence profile for patients receiving erector spinae vs serratus anterior plane block in breast cancer surgeries

RR risk ratio, *MD* mean difference, *SMD* standardized mean difference, *AUC* area under curve, *CI* confidence interval, *SA* sensitivity analysis

on visual inspection of the funnel plot (online supplemental appendix C); thus, the GRADE strength of evidence was moderate (Table 2).

Secondary outcomes

Postoperative pain score at 0, 6, 8, 12, and 24 h (static)

Seven studies [30, 31, 34–38] reported postoperative pain scores at 0 h (static). No significant differences were observed between the two groups for this outcome (SMD = -0.24 [-1.61,1.14], p=0.74, $l^2=97\%$) (Fig. 5a). High in-study heterogeneity was seen. Sensitivity analysis was performed by removing studies based on usage of benzodiazepine, i.e., alprazolam 0.25 mg [34, 37] and midazolam 0.01–0.02/mg/kg [36] on the day of surgery, (SMD = 0.47 [-0.10,1.05], P=0.11, $l^2=78\%$) heterogeneity reduced to 78% (Fig. 5b). Visually, the funnel plot appeared asymmetrical (online supplemental appendix *C*).

Postoperative pain score at 6 h (static) was assessed by six studies [30, 31, 33, 36–38]. The pooled analysis showed that pain score at 6 h did not vary significantly with either plane block (SMD=-0.21 [-0.46, 0.04], p=0.10, $l^2=13\%$) (Fig. 5c). Heterogeneity was found to be low. There was an asymmetrical appearance on the visual inspection of the funnel plot (online supplemental appendix C).

Three studies [32, 34, 35] evaluated postoperative pain score at 8 h (static). According to the pooled analysis, none of the plane blocks were superior to the other (SMD = -1.14 [-4.75, 2.48], p = 0.54, $I^2 = 99\%$) (Fig. 5d). Heterogeneity was found to be high. In order to reduce heterogeneity, sensitivity analysis was done by removing a study based on the usage of alprazolam 0.25 mg [34] (SMD = -0.10 [-0.40, 0.19], p = 0.48, $I^2 = 0\%$) (Fig. 5e). The funnel plot observed an asymmetrical pattern (online supplemental appendix C).

Postoperative pain score at 12 h (static) was assessed by nine studies [30–38]. The pooled analysis revealed insignificant differences among both the plane blocks (SMD = -0.16 [-1.44, 1.13], P=0.81, $I^2=97\%$) (Fig. 5f). High in-study heterogeneity was observed. Sensitivity analysis by removing studies based on the usage of benzodiazepine, i.e., alprazolam 0.25 mg [34, 37] and midazolam 0.01–0.02/mg/kg [36] on the day of surgery (SMD = -0.10, [-1.13,0.94] p=0.85, $I^2=95\%$) failed to

	Favor	ITS [ESPI	8]	Favo	urs [SAP	8]		Mean Difference		Mean Difference
Study or Subgroup	Mean	\$D	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Eldemrdash 2019 [26]	4	2	25	7	2	25	13.5%	-3.00 [-4.11, -1.89]	2019	-
Wang 2019 [28]	48	9.6	50	45.6	7.2	50	7.5%	2.40 [-0.93, 5.73]	2019	
Elsabeeny 2020 [27]	4.2	1.64	25	4	1.55	25	14.0%	0.20 [-0.68, 1.08]	2020	+
Jiang 2021 [29]	1.54	0.615	25	0.96	0.225	25	14.9%	0.58 [0.32, 0.84]	2021	
Shrivastava 2021 [34]	27.36	3.69	30	31.43	1.88	30	12.5%	-4.07 [-5.55, -2.59]	2021	
Ahuja 2022 [31]	5.67	0.84	40	7.52	1.95	40	14.5%	-1.85 [-2.51, -1.19]	2022	-
Sagar 2022 [33]	185	36.635	20	227.5	47.226	20	0.2%	-42.50 [-68.69, -16.31]	2022	•
Bedewy 2023 [32]	4.6513	2.4653	20	7.65	6.26	20	8.4%	-3.00 [-5.95, -0.05]	2023	
Nyima 2023 [30]	3.13	1.44	40	4.33	1.69	40	14.4%	-1.20 [-1.89, -0.51]	2023	-
Total (95% CI)			275			275	100.0%	-1.41 [-2.70, -0.13]		•
Heterogeneity: Tau* = 2.8	86; Chi#=	134.19, 0	df = 8 (F	< 0.00	001); P=	94%				-10 -5 0 5 10
Test for overall effect Z =	2.16 (P =	0.03)								Favours [ESPB] Favours [SAPB]

		ESPB			SAPB			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% Cl
1.25.1 Bupivacaine										
Elsabeeny 2020 [27]	4.2	1.64	25	4	1.55	25	14.0%	0.20 [-0.68, 1.08]	2020	+
Shrivastava 2021 [34]	1.54	0.615	25	0.96	0.225	25	14.9%	0.58 [0.32, 0.84]	2021	
Sagar 2022 [33]	185	36.635	20	227.5	47.226	20	0.2%	-42.50 [-68.69, -16.31]	2022	←
Bedewy 2023 [32]	4.6513	2.4653	20	7.65	6.26	20	8.4%	-3.00 [-5.95, -0.05]	2023	
Subtotal (95% CI)			90			90	37.6%	-0.32 [-1.85, 1.22]		+
Heterogeneity: Tau ^a = 1.	37; Chi# =	16.54, dt	(= 3 (P	= 0.000	9); I ² = 82	2%				
Test for overall effect Z =	= 0.40 (P =	0.69)								
1.25.3 Others										
Eldemrdash 2019 [26]	4	2	25	7	2	25	13.5%	-3.00 [-4.11, -1.89]	2019	-
Wang 2019 [28]	48	9.6	50	45.6	7.2	50	7.5%	2.40 [-0.93, 5.73]	2019	
Jiang 2021 [29]	27.36	3.69	30	31.43	1.88	30	12.5%	-4.07 [-5.55, -2.59]	2021	
Ahuja 2022 [31]	5.67	0.84	40	7.52	1.95	40	14.5%	-1.85 [-2.51, -1.19]	2022	•
Nyima 2023 [30]	3.13	1.44	40	4.33	1.69	40	14.4%	-1.20 [-1.89, -0.51]	2023	
Subtotal (95% CI)			185			185	62.4%	-2.01 [-3.15, -0.87]		•
Heterogeneity: Tau ^a = 1.	22; Chi#=	22.43, dt	(= 4 (P	= 0.000	2); I ² = 82	2%				
Test for overall effect Z =	: 3.45 (P =	0.0006)								
Total (95% CI)			275			275	100.0%	-1.41 [-2.70, -0.13]		•
Heterogeneity: Tau ^a = 2.	86; Chi# =	134.19,	ff = 8 (F	× 0.00	001); *=	94%				
Test for overall effect Z =	2.16 (P=	0.03)								-10 -5 0 5 10
Test for subgroup differe			df = 1 /	P = 0.01	0 17 - 66	0.96				Favours [ESPB] Favours [SAPB]

		E\$PB			SAPB			Mean Difference		Mean Difference
Study or Subgroup	Mean	\$D	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
1.25.1 Bupivacaine										
Elsabeeny 2020 [27]	4.2	1.64	25	4	1.55	25	14.1%	0.20 (-0.68, 1.08)	2020	+
Shrivastava 2021 [34]	1.54	0.615	25	0.96	0.225	25	15.1%	0.58 [0.32, 0.84]	2021	
Sagar 2022 [33]	185	38.635	20	227.5	47.226	20	0.0%	-42.50 [-68.69, -16.31]	2022	
Bedewy 2023 [32]	4.6513	2.4653	20	7.65	6.28	20	8.2%		2023	
Subtotal (95% CI)			70			70	37.5%	0.12 [-0.83, 1.07]		•
Heterogeneity: Tau ^a = 0.	42; Chi ² =	6.18, df=	: 2 (P =	0.05);	a = 68%					
Test for overall effect Z	= 0.25 (P =	: 0.80)								
1.25.3 Others										
Eldemrdash 2019 [26]	4	2	25	7	2	25	13.6%	-3.00 [-4.11, -1.89]	2019	-
Wang 2019 [28]	48	9.6	50	45.6	7.2	50	7.3%	2.40 [-0.93, 5.73]	2019	
Jiang 2021 [29]	27.36	3.69	30	31.43	1.88	30	12.5%	-4.07 [-5.55, -2.59]	2021	
Ahuja 2022 [31]	5.67	0.84	40	7.52	1.95	40	14.6%	-1.85 [-2.51, -1.19]	2022	-
Nyima 2023 [30]	3.13	1.44	40	4.33	1.69	40	14.5%		2023	
Subtotal (95% CI)			185			185	62.5%	-2.01 [-3.15, -0.87]		•
Heterogeneity: Tau ^a = 1.	22; Chi# =	22.43, df	= 4 (P	= 0.000	02); I [#] = 82	2%				
Test for overall effect Z	= 3.45 (P =	0.0006)								
Total (95% CI)			255			255	100.0%	-1.32 [-2.56, -0.07]		•
Heterogeneity: Tau ^a = 2.	65; Chi#=	124.12,	f = 7 ()	P < 0.00	0001); P=	94%			-	-10 -5 0 5 10
Test for overall effect Z	2.07 (P	0.04)								-10 -5 0 5 10 Favours [ESPB] Favours [SAPB]
Test for subgroup different	ences: Ch	#= 7.89.	df = 1 (P=0.0	05), *= 8	7.3%				ravous (cond) ravous (overb)

Fig. 4 a Forest plot of 24-h postoperative oral morphine (mg) equivalent consumption. The MD estimates for each study are represented by squares and the lines passing through them represent 95% CI. The diamond represents the overall pooled estimate. **b** 24-h postoperative oral morphine (mg) equivalent consumption (forest plot for subgroup analysis). **c** 24-h postoperative oral morphine (mg) equivalent consumption (forest plot for subgroup analysis). **c** 24-h postoperative oral morphine (mg) equivalent consumption (forest plot for subgroup analysis). **c** 24-h postoperative oral morphine (mg) equivalent consumption (forest plot for subgroup analysis). **c** 24-h postoperative oral morphine (mg) equivalent consumption (forest plot for subgroup analysis). **c** 24-h postoperative oral morphine (mg) equivalent consumption (forest plot for subgroup analysis). **c** 24-h postoperative oral morphine (mg) equivalent consumption (forest plot for subgroup analysis). **c** 24-h postoperative oral morphine (mg) equivalent consumption (forest plot for subgroup analysis). **c** 24-h postoperative oral morphine (mg) equivalent consumption (forest plot for subgroup analysis). **c** 24-h postoperative oral morphine (mg) equivalent consumption (forest plot for sensitivity analysis in group bupivacaine). MD mean difference, CI confidence interval, IV inverse variance, SD standard deviation, ESPB erector spinae plane block, SAPB serratus anterior plane block

reduce significant heterogeneity. The funnel plot demonstrated symmetry (online supplemental appendix C).

All nine studies [30–38] reported postoperative pain score at 24 h (static). Both regional blocks yielded similar postoperative pain score (static) at 24 h according to the pooled analysis (SMD = -0.13 [-1.00, 0.74], p=0.77, $I^2=95\%$) (Fig. 5g). Heterogeneity was seen to be high. On conducting sensitivity analysis by removing studies based on usage of benzodiazepine, i.e., alprazolam 0.25 mg [34, 37] and midazolam 0.01–0.02/mg/kg [36] on the day of surgery (SMD = -0.16, [-0.36, 0.04], p=0.11), heterogeneity dropped to 0% (Fig. 5h). Symmetry was observed on the funnel plot (online supplemental appendix C). Overall, the GRADE strength of evidence was low in static pain score at 24 h (Table 2).

Postoperative pain scores at 0, 8, 12, and 24 h (dynamic)

Two studies [34, 35] assessed postoperative pain score at 0 h (dynamic). The pooled analysis showed insignificant results (SMD = -265.41 [-789.93, 259.10], P=0.32, $I^2=99\%$) (Fig. 6a). High in-study heterogeneity was observed. The funnel plot appeared symmetrical (online supplemental appendix C), indicating the absence of publication bias.

Three studies [32, 34, 35] reported postoperative pain scores at 8 h (dynamic). Insignificant results were yielded through the pooled analysis (SMD = -0.81 [-4.43, 2.81], p=0.66, $I^2=99\%$) (Fig. 6b). Heterogeneity was seen to be high. Sensitivity analysis was conducted by removing a study based on the usage of alprazolam 0.25 mg [34] (SMD = -0.09 [-0.38, 0.20], p=0.54, $I^2=0\%$), and heterogeneity dropped to 0% (Fig. 6c). Visually, the funnel plot exhibited asymmetry (online supplemental appendix C).

Four studies [32–35] evaluated postoperative pain scores at 12 and 24 h (dynamic). The pooled analysis revealed insignificant differences between the two groups (SMD = -0.46 [-2.72, 1.81], p=0.69, $I^2=98\%$) (Fig. 6d) and groups (SMD = -0.46 [-2.72, 1.81], p=0.69, $I^2=98\%$) (Fig. 6f). High in-study heterogeneity was seen in both outcomes. To reduce the heterogeneity, sensitivity analysis was conducted by excluding a study [34] based on the usage of alprazolam 0.25 mg (SMD = -0.09[-0.44, 0.25], p=0.59, $I^2=44\%$) (Fig. 6e) and (SMD = -0.10 [-0.35, 0.16], p=0.46, $I^2=0\%$) (Fig. 6g), respectively. Both the funnel plots exhibited an asymmetrical pattern (online supplementary appendix C). Overall, the GRADE strength of evidence was moderate for dynamic pain score outcome at 24 h (Table 2).

Number of patients requested analgesia in the first 24 h postoperatively

Four studies [31, 32, 34, 38] assessed the number of patients requesting analgesics in the first 24 h postoperatively. The pooled analysis revealed that the number of patients who received SAPB showed increased demand of analgesia in the first 24 h postoperatively. Statistically significant difference was obtained between the two groups (RR=1.28 [1.00,1.63], p=0.05, $I^2=0\%$) (Fig. 7). Low in-study heterogeneity was observed. There was an asymmetrical appearance on visual inspection of the funnel plot (online supplemental appendix C); thus, the GRADE strength of evidence was high (Table 2).

Time to first postoperative analgesic use (hours)

Six articles [30, 31, 33–35, 37] analyzed the time to first postoperative analgesic use (hours). Significant results were obtained. The pooled analysis exhibited that the patients receiving ESPB took more time to first postoperative analgesic use (MD=1.55, [1.02, 2.09], p = <0.01, $I^2 = 79\%$) (Fig. 8a). High in-study heterogeneity was seen. On performing sensitivity analysis by removing studies based on usage of ropivacaine [33–35] and usage of alprazolam 0.25 mg on the day of surgery [34] (MD=1.49 [1.15,1.83], p = <0.01, $I^2 = 0\%$), heterogeneity dropped to 0% (8b). The funnel plot appeared symmetrical (online supplemental appendix C), indicating the absence of publication bias. Overall, the GRADE strength of evidence was high (Table 2).

Patient satisfaction score

It was assessed by two articles [33, 35]. Patients in both groups demonstrated similar satisfaction according to the pooled analysis (MD = -0.33 [-0.66, -0.01], p=0.05, $I^2=0\%$) (Fig. 9). No in-study heterogeneity was observed. There was a symmetrical appearance on visual inspection of the funnel plot (online supplemental appendix C). The GRADE strength of evidence was found to be high (Table 2).

(See figure on next page.)

Fig. 5 a Postoperative pain scores (static) at 0 h. b Postoperative pain scores (static) at 0 h (forest plot for sensitivity analysis). c Postoperative pain scores (static) at 6 h. d Postoperative pain scores (static) at 8 h. e Postoperative pain scores (static) at 8 h (forest plot for sensitivity analysis). f Postoperative pain scores (static) at 12 h. g Postoperative pain scores (static) at 24 h. h Postoperative pain scores (static) at 24 h (forest plot for sensitivity analysis). f Postoperative pain scores (static) at 12 h. g Postoperative pain scores (static) at 24 h. h Postoperative pain scores (static) at 24 h (forest plot for sensitivity analysis). SMD standard mean difference, CI confidence interval, IV inverse variance, SD standard deviation, ESPB erector spinae plane block, SAPB serratus anterior plane block

| Study or Subgroup
Eldemrdash 2019 [26]
 |
 | 60.1
 | [etal |
 | APB | latal M | Volaht
 | Std. Mean Differen | | Vent
 | Std. Mean Dif | |

--
---	--
--	--
---	--
 | Mean
1.35
 | SD 1
2.35
 | 25 | Mean
1.35
 | SD 1
2.35 | | Veight
16.7%
 | IV, Random, 9
0.00 [-0.55 | | Year
2019
 | IV, Random, | 95% CI |
| Elsabeeny 2020 [27]
 | 2
 | 1.01
 | |
 | 0.089 | 25 | 16.6%
 | 1.36 [0.74 | 1, 1.98] | 2020
 | | |
| Shrivastava 2021 [34]
 | 2
 | 0.001
 | 25 |
 | 0.001 | | 16.7%
 | 0.00 [-0.55 | | 2021
 | | |
| Ahuja 2022 [31]
Sagar 2022 [33]
 | 2.33
 | 4.42
0.489
 | 40
20 | 0.5
 | 0.76 | | 16.8%
16.5%
 | 0.57 [0.12 | | 2022 2022
 | | - |
| Nyima 2023 [30]
 | 0.2
 | 0.001
 | 40 |
 | 0.001 | 40 |
 | -188.17 [-218.07, -1 | | 2023 4
 | | |
| Bedewy 2023 [32]
 | 1.3598
 | 0.7978
 | 20 2 | 1403 1
 | .5957 | 20 | 16.5%
 | -0.61 [-1.24 | , 0.03] | 2023
 | - | |
| Total (95% CI)
 |
 |
 | 195 |
 | | | 00.0%
 | -0.24 [-1.61 | , 1.14] |
 | | - |
| Heterogeneity: Tau ^a = 2.
Test for overall effect Z :
 | 87; Chi ² = 1
= 0.34 (P =
 | 179.08, df
0.74)
 | = 6 (P < | 0.00001
 | 1); I² = 97 | % |
 | | |
 | -2 -1 0
Favours [ESPB] Fa | 1 2
wours [SAPB] |
|
 |
 | ESPB
 | |
 | APB | |
 | Std. Mean Differe | |
 | Std. Mean D | |
| Study or Subgroup
Eldemrdash 2019 [26]
 | Mean
1.35
 | 2.35
 | Total
25 | Mean
1.35
 | SD
2.35 | 25 | 24.8%
 | IV, Random,
0.00 (-0.5 | | Year
2019
 | IV, Random | , 95% CI |
| Elsabeeny 2020 [27]
 | 2
 | 1.01
 | 25 | 1.011
 | 0.089 | 25 | 23.4%
 | 1.36 [0.7 | | 2020
 | | |
| Shrivastava 2021 [34]
 | 2.33
 | 0.001
 | 25
40 | 2
 | 0.001 | 25
40 | 24.8%
 | 0.00 (-0.5 | | 2021 2022
 | - | |
| Ahuja 2022 [31]
Sagar 2022 [33]
 | 0.35
 | 0.489
 | 20 | 0.55
 | 0.51 | 20 | 0.0%
 | 0.57 [0.1
-0.39 [-1.0 | | 2022
 | | |
| Nyima 2023 [30]
 | 0.2
 | 0.001
 | 40 | 0.39
 | 0.001 | 40 | 0.0%
 | -188.17 [-218.07, - | 158.26] | 2023
 | | |
| Bedewy 2023 [32]
 | 1.3598
 | 0.7978
 | 20 | 2.1403
 | 1.5957 | 20 | 0.0%
 | -0.61 [-1.2 | 4, 0.03] | 2023
 | | |
| Total (95% CI)
Heterogeneity: Tau ² = 0
Test for overall effect: Z
 |
 |
 | 115
= 3 (P = | 0.004);
 | l² = 78% | 115 | 100.0%
 | 0.47 [-0.1 | 0, 1.05] | -
 | -2 -1 0 | |
|
 | 1.010
 |
 | |
 | | |
 | | |
 | Favours [ESPB] | |
| Study or Subgroup
 | Mean
 | ESPB
SD
 | Total | Mean
 | SAPB
SD | Total | Weigh
 | Std. Mean Differ
IV, Random, St | | Year
 | | Difference
m, 95% Cl |
| Eldemrdash 2019 [26]
 |
 | 2.358
 | 25 | mean
3
 | 3.14 | 25 | 17.49
 | | | 2019
 | iv, ridiluc | |
| Elsabeeny 2020 [27]
 | 2
 | 0.001
 | 25 | 2
 | 1 | 25 | 17.59
 | | | 2020
 | | |
| Jiang 2021 [29]
 | 0.76
 | 0.6539
 | 30 |
 | 0.8096 | 30 | 20.49
 | -0.08 [-0.59 | 9, 0.43] | 2021
 | | <u> </u> |
| Shrivastava 2021 [34]
 | 2
 | 0.001
 | 25 | 2 25
 | 0.001 | 25 | 17.59
 | | | 2021
 | | |
| Sagar 2022 [33]
Bedewy 2023 [32]
 | 1.7
 | 0.657
 | 20
20 | 2.35
 | 0.745 0.797 | 20
20 | 13.09
 | | | 2022 2023
 | | <u> </u> |
|
 | 2.000
 |
 | | 2.000
 | 0.101 | |
 | | |
 | - | |
| Total (95% CI)
 | 0.01: 01:7
 | - 6 70 -
 | 145 | = 0.22
 | R = 10~ | | 100.04
 | -0.21 [-0.46 | 5, 0.04] |
 | | |
| Heterogeneity: Tau ² = 0
Test for overall effect: 2
 |
 |
 | = 5 (P | - 0.33);
 | r = 13% | |
 | | |
 | | 0 0.5 1
Favours [SAPB] |
|
 | F
 | SPB
 | | SAP
 | B | | _
 | Std. Mean Differer | nce |
 | | Difference |
| Study or Subgroup
 | Mean
 | SD To
 | tal Me |
 | SD Tot | al We | ight
 | IV, Random, 9 | | Year
 | | m, 95% Cl |
| Wang 2019 [28]
 | 3.1
 |
 | | 3.3
 | | 60 49 | .9%
 | -0.19 [-0.58 | | 2019
 | | |
| Ahuja 2022 [31]
 |
 |
 | |
 | | | .9%
 | 0.00 [-0.44 | | 2022
 | | |
| Nyima 2023 [30]
 | 1.88 0
 | .001
 | 40 2 | .38 0.0
 | 101 4 | 0 0 | 1.2% -4
 | 95.18 [-573.87, -4 | 16.49] | 2023 4
 | | |
| Total (95% CI)
 |
 | 1
 | 30 |
 | 13 | 100 | 0.0%
 | -1.14 [-4.75 | 6, 2.48] |
 | • | |
| Heterogeneity: Tau ² =
 |
 |
 | , df = 2 | (P < 0.0
 | 00001); 1 | = 999 | 6
 | | | -
 | -50 -25 | 25 5 |
| Test for overall effect.
 | Z = 0.62 (F
 | P = 0.54)
 | |
 | | |
 | | |
 | | Favours [SAPB] |
|
 |
 |
 | |
 | | |
 | | |
 | | |
|
 | ES
 | DR
 | | SAPE
 | D | |
 | | |
 | | |
| Chudu on Cubarran
 |
 |
 | |
 | | |
 | td. Mean Difference | Ce |
 | | |
| Study or Subgroup
 | Mean
 | SD Tot
 | al Me |
 | | I Wei |
 | td. Mean Differend
IV, Random, 95 | | Year
 | Std. Mean D
IV, Randon | |
| Study or Subgroup
Wang 2019 [28]
 | 3.1
 | 1.1 6
 | 50 3 | an 5
3.3
 | | | ght
 | td. Mean Differend
IV, Random, 99
-0.19 (-0.58, | 5% CI | Year
2019
 | IV, Randon | |
| Wang 2019 [28]
Ahuja 2022 [31]
 | 3.1
0.64 (
 | 1.1 5
0.76 4
 | 50 3
10 0. | an 5
3.3
64 0.7
 | SD Tota
1 50
76 40 | 0 55.
0 44. | ght
4%
6%
 | -0.19 [-0.58,
0.00 [-0.44, | 0.20]
0.44] | 2019
2022
 | | |
| Wang 2019 [28]
 | 3.1
0.64 (
 | 1.1 5
0.76 4
 | 50 3
10 0. | an 5
3.3
 | SD Tota
1 50
76 40 | 0 55.
0 44. | ght
4%
6%
 | IV, Random, 9
-0.19 [-0.58, | 0.20]
0.44] | 2019
 | | |
| Wang 2019 [28]
Ahuja 2022 [31]
 | 3.1
0.64 (
 | 1.1 5
0.76 4
001 4
 | 50 3
10 0. | an 5
3.3
64 0.7
 | 5D Tota
1 50
76 40
01 40 | 0 55.
0 44. | ght
4%
6%
0% -49
 | -0.19 [-0.58,
0.00 [-0.44, | 5% CI
0.20]
0.44]
6.49] | 2019
2022
 | | |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Heterogeneity: Tau ^a =
 | 3.1
0.64 (
1.88 0.
0.00; Chi ^a
 | 1.1 5
0.76 4
001 4
= 0.40, dt
 | 50 3
10 0.
10 2.
10 | an 5
3.3
64 0.1
38 0.00
 | 5D Tota
1 51
76 41
01 41
91 | 0 55.
0 44.
0 0. | ght
4%
6%
0% -49
 | IV, Random, 99
-0.19 [-0.58,
0.00 [-0.44,
95.18 [-573.87, -41 | 5% CI
0.20]
0.44]
6.49] | 2019
2022
 | IV, Randon | n, 95% Cl |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
 | 3.1
0.64 (
1.88 0.
0.00; Chi ^a
 | 1.1 5
0.76 4
001 4
= 0.40, dt
 | 50 3
10 0.
10 2.
10 | an 5
3.3
64 0.1
38 0.00
 | 5D Tota
1 51
76 41
01 41
91 | 0 55.
0 44.
0 0. | ght
4%
6%
0% -49
 | IV, Random, 99
-0.19 [-0.58,
0.00 [-0.44,
95.18 [-573.87, -41 | 5% CI
0.20]
0.44]
6.49] | 2019
2022
 | IV, Randon | n, 95% CI |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Héterogeneity: Tau ^a =
Test for overall effect 2
 | 3.1
0.64 (
1.88 0.
0.00; Chi ^a
Z = 0.70 (P
 | 1.1 5
0.76 4
001 4
= 0.40, dt
2 = 0.48)
 | 50 3
10 0.
10 2
90
f=1 (P | an <u>\$</u>
3.3
64 0.3
38 0.00
= 0.53);
5
 | SD Tota
1 51
76 41
01 41
91
1 ² = 0%
SAPB | 0 55.
0 44.
0 0. | ght
4%
6%
0% -49
 | IV, Random, 9
-0.19 [-0.58,
0.00 [-0.44,
95.18 [-573.87, -41
-0.10 [-0.40,
Std. Mean Differe | 5% CI
0.20] :
0.44] :
6.49] :
0.19]
ence | 2019
2022
2023
 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean D | h, 95% Cl
25 50
Favours [SAPB] |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% Cl)
Heterogeneity: Tau ² =
Test for overall effect 2
Study or Subgroup
 | 3.1
0.64 (
1.88 0.
0.00; Chi ^a
Z = 0.70 (P
Mean
 | 1.1 4
0.76 4
001 4
= 0.40, dt
= 0.40, dt
= 0.48)
ESPB
SD
 | 50 3
10 0.
10 2
90
f= 1 (P
Total | an <u>5</u>
3.3
64 0.7
38 0.00
= 0.53);
<u>Mean</u>
 | SD Tota 1 50 76 40 90 40 91 41 91 41 93 17 17 50 18 50 | 0 55.
0 44.
0 0.
0 100.
Total | ght
4%
6%
0% -49
.0%
 | IV, Random, 9:
-0.19 [-0.58,
0.00 [-0.44,
95.18 [-573.87, -41
-0.10 [-0.40,
Std. Mean Differr
IV, Random, | 5% CI
0.20] :
0.44] :
6.49] :
0.19]
ence | 2019
2022
2023
 | IV, Randor
-50 -25 0
Favours [ESPB] | h, 95% Cl
25 50
Favours [SAPB] |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% Cl)
Heterogeneity: Tau ^a =
Test for overall effect 2
Study or Subgroup
Wang 2019 [28]
 | 3.1
0.64 (
1.88 0.
0.00; Chi ^a
Z = 0.70 (P
 | 1.1 5
0.76 4
001 4
= 0.40, dt
2 = 0.48)
 | 50 3
10 0.
10 2
90
f=1 (P | an <u>\$</u>
3.3
64 0.3
38 0.00
= 0.53);
5
 | SD Tota
1 51
76 41
01 41
91
1 ² = 0%
SAPB | 0 55.
0 44.
0 0. | ght
4%
6%
0% -49
 | IV, Random, 95
-0.19 [-0.58,
0.00 [-0.44,
95.18 [-573.87, -41
-0.10 [-0.40,
Std. Mean Differo
IV, Random,
0.00 [-0.3 | 5% CI
0.20] :
0.44] :
6.49] :
0.19]
ence
, 95% CI
39, 0.39] | 2019
2022
2023
<u>Year</u>
2019
 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean D | h, 95% Cl
25 50
Favours [SAPB] |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% Cl)
Heterogeneity, Tau* =
Test for overall effect 2
Study or Subgroup
Wang 2019 [26]
Eldernrdash 2019 [26]
Elsaberray 2020 [27]
 | 3.1
0.64 (
1.88 0.
0.00; Chi ^a
Z = 0.70 (P
<u>Mean</u>
3.3
 | 1.1 5
0.76 4
0001 4
= 0.40, dt
P = 0.48)
ESPB
SD
1.1
2.65
0.089
 | 50 3
10 0.
10 2
10 7
10 2
10
10 7
10
10
10
10
10
10
10
10
10
10
10
10
10 | an <u>\$</u>
3.3
64 0.7
38 0.00
= 0.53);
<u>Mean</u>
3.3
 | 5D Tota
1 51
76 41
01 41
91
1 ^a = 0%
5D
1.1
3.93
0.089 | 0 55.
0 44.
0 0.
0 100.
<u>Total</u>
50 | ght
4%
6%
0% -49
.0%
<u>Weight</u>
14.5%
14.3%
 | IV, Random, 9:
-0.19 [-0.58,
0.00 [-0.44,
95.18 [-573.87, -41
-0.10 [-0.40,
Std. Mean Differr
IV, Random, | 5% CI
0.20] :
0.44] :
6.49] :
0.19]
ence
<u>95% CI</u>
39, 0.39]
94, 0.18] | 2019
2022
2023
<u>Year</u>
2019
2019
 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean D | h, 95% Cl
25 50
Favours [SAPB] |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Heterogeneity: Tau ^a =
Test for overall effect 2
Study or Subgroup
Wang 2019 [28]
Eldemdash 2019 [26]
Elsabeery 2020 [27]
 | 3.1
0.64 (
1.88 0.
0.00; Chi ^µ
Z = 0.70 (P
<u>Mean</u>
3.3
2.34
1.011
2
 | 1.1 5
0.76 4
001 4
s = 0.40, dt
c = 0.48)
ESPB
SD
1.1
2.65
0.089
0.001
 | 50 3
10 0.1
10 2.2
10
10
10
10
10
10
10
10
25
25
25
25 | an 5
3.3
64 0.3
38 0.00
= 0.53);
Mean
3.3
3.64
1.011
1
 | SD Tota 1 50 76 40 90 90 1ª = 0% 90 SAPB SD 1.1 3.93 0.089 0.001 | 0 55.
0 44.
0 0.
0 100.
Total
50
25
25
25
25 | ght
4%
6%
0% -49
.0%
<u>Weight</u>
14.5%
14.3%
0.0%
 | V, Random, 9
-0.19 [-0.58,
0.00 [-0.44,
95.18 [-57.387, -41
-0.10 [-0.40,
Std. Mean Differe
V, Random,
0.00 [-0.3
-0.38 [-9
-0.38 [-9
-0.38 [-9
-0.39 [-9] -0.39 [-9
-0.39 [-9] | 5% CI
0.20]
0.44]
6.49]
0.19]
ence
, 95% CI
39, 0.39]
94, 0.18]
55, 0.55]
1185, 29] | 2019
2022
2023
<u>Year</u>
2019
2019
2020
2021 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean D | h, 95% Cl
25 50
Favours [SAPB] |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% Cl)
Helerogeneity, Tau* =
Test for overall effect 2
Study of Subgroup
Wang 2019 [28]
Elderndash 2019 [26]
Elsabeern 2020 [27]
Shrivastava 2021 [24]
 | 3.1
0.64 (
1.88 0.
0.00; Chi [#]
Z = 0.70 (P
Mean
3.3
2.34
1.011
2
2.1.24
 | 1.1 5
0.76 4
001 4
= 0.40, dt
= 0.48)
ESPB
SD
1.1
2.65
0.089
0.001
0.685
 | 50 3
10 0.1
10 2.2
10
10
10
10
10
10
10
10
25
25
25
30 | an 5
3.3
64 0.7
38 0.00
= 0.53);
Mean
3.3
3.64
1.011
1
1.28
 | SD Tota 1 50 76 41 01 41 91 91 P = 0% 50 1.1 3.93 0.089 0.001 0.0716 0.716 | 0 55.
0 44.
0 0.
0 100.
Total
50
25
25
30 | ght
4%
6%
0% -49
.0%
Weight
14.5%
14.3%
0.0%
14.3%
 | IV, Random, 9! -0.19 [-0.58, 0.00 [-0.44, 95.18 [-573.87, -41 -0.10 [-0.40, Std. Mean Differr IV, Random, 0.00 [-0.38, -00] 98.29 [703.29, 1 -0.00 [-0.36, -00] 994.29 [703.29, 1 -0.00 [-0.56, -00] | 5% CI
0.20] :
0.44] :
6.49] :
0.19]
ence
<u>, 95% CI</u>
39, 0.39]
94, 0.18]
55, 0.55]
1185.293
56, 0.45] | 2019
2022
2023
<u>Year</u>
2019
2019
2020
2021
2021
 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean D | h, 95% Cl
25 50
Favours [SAPB] |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Heterogeneity: Tau ^a =
Test for overall effect 2
Study or Subgroup
Wang 2019 [28]
Eldemdash 2019 [26]
Elsabeery 2020 [27]
 | 3.1
0.64 (
1.88 0.
0.00; Chi ^µ
Z = 0.70 (P
<u>Mean</u>
3.3
2.34
1.011
2
 | 1.1 5
0.76 4
001 4
= 0.40, dt
= 0.40, dt
= 0.48)
ESPB
SD
1.1
2.65
0.089
0.001
0.685
0.681
0.76
 | 50 3
10 0.1
10 2.2
10
10
10
10
10
10
10
10
25
25
25
25 | an 5
3.3
64 0.7
38 0.00
= 0.53);
Mean
3.3
3.64
1.011
1.28
2.25
0.64
 | SD Tota 1 50 76 40 90 90 1ª = 0% 90 SAPB SD 1.1 3.93 0.089 0.001 | 0 55.
0 44.
0 0.
0 100.
Total
50
25
25
25
25 | ght
4%
6%
0% -49
.0%
<u>Weight</u>
14.5%
14.3%
0.0%
 | IV, Random, 9' -0.19 [-0.58,
0.00 [-0.44,
25.18 [-57.387, -41 -0.10 [-0.40, Std. Mean Differr
IV, Random,
0.00 [-0.3 -0.310 [-0.40, -0.01 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, | 5% CI
0.20]
0.44]
6.49]
0.19]
ence
<u>95% CI</u>
39, 0.39]
94, 0.18]
55, 0.55]
1185.29]
56, 0.45]
9, 0.37]
52, 0.26] | 2019
2022
2023
<u>Year</u>
2019
2019
2020
2021
2021
2022
2022
 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean D | h, 95% Cl
25 50
Favours [SAPB] |
| Wang 2019 [28] Ahuja 2022 [31] Nyima 2023 [30] Total (95% CI) Heterogeneilty, Tau* = 1 Study of Subgroup Vang 2019 [28] Eldemdash 2019 [26] Eldemdash 2019 [26] Shmistawa 2021 [27] Jaing 2021 [28] Shmistawa 2021 [29] Jaing 2021 [29] Anuja 2022 [23] Anuja 2022 [29]
 | 3.1
0.64 (
1.88 0.
0.00; Chi [#]
Z = 0.70 (P
Mean
3.3
2.34
1.011
2
1.24
1.6
0.5
5
1.95
 | 1.1 5
0.76 4
001 4
= 0.40, dt
= 0.48)
ESPB
SD
1.1
2.65
0.089
0.001
0.685
0.685
0.681
0.76
 | 50 3
10 0.1
10 2
10
10 2
10
10
10
10
10
10
10
10
10
10 | an 5
3.3
64 0.3
38 0.00
= 0.53);
Mean
3.64
1.011
1.28
2.25
0.64
2.805
 | SD Tota 1 50 76 40 91 40 91 40 92 0% 1.1 3.93 3.93 0.089 0.001 0.716 0.765 0.001 | 0 55.
0 44.
0 0.
0 100.
Total
50
25
25
25
25
30
20
40
40 | ght
4%
6%
0% -4
0%
-4
14.5%
14.3%
14.3%
14.3%
14.3%
14.4%
0.0%
 | IV, Random, 9 -0.19 [0.56,
0.00 [0.04,
55.18 [-57.387, -41 -0.10 [-0.40, Std. Mean Differt
IV, Random,
0.00 [0.3
-0.38 [0.9
0.00 [0.5]
-0.38 [1.0]
-0.06 [0.5]
-1.03 [1.6]
-0.48 [0.6]
-0.48 [0.6] | 5% CI
0.20]
0.44]
6.49]
0.19]
ence
<u>95% CI</u>
39,0.39]
94,0.18]
55,0.55]
1185.29]
56,0.45]
9,-0.37]
52,0.26]
-712.19] | 2019
2022
2023
2023
2023
2029
2019
2020
2021
2021
2022
2022
2023
 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean D | h, 95% Cl
25 50
Favours [SAPB] |
| Wang 2019 [28] Ahuja 2022 [31] Nyima 2023 [30] Total (95% CI) Heterogeneity: Tau* = Test for overall effect 2 Study of Subgroup Wang 2019 [28] Eldemrdish 2019 [28] Elsabeers 2020 [27] Shrivastava 2021 [24] Sagar 2022 [33] Ahuja 2022 [31]
 | 3.1
0.64 (
1.88 0.
0.00; Chi ^a
Z = 0.70 (P
Mean
3.3
2.34
1.011
2
1.24
1.6
0.5
 | 1.1 5
0.76 4
001 4
= 0.40, dt
= 0.40, dt
= 0.48)
ESPB
SD
1.1
2.65
0.089
0.001
0.685
0.681
0.76
 | 50 3
10 0.1
10 2
10
10 2
10
10
10
10
10
10
10
10
10
10 | an 5
3.3
64 0.3
38 0.00
= 0.53);
Mean
3.64
1.011
1.28
2.25
0.64
2.805
 | SD Tota 1 50 76 40 90 90 1 ² = 0% 90 SAPB 50 1.1 3.93 0.089 0.001 0.716 0.55 0.76 0.76 | 0 55.
0 44.
0 0.
0 100.
Total
50
25
25
25
25
30
20
40 | ght
4%
6%
0% -4
0%
-4
14.5%
14.3%
14.3%
14.3%
14.3%
14.4%
 | IV, Random, 9' -0.19 [-0.58,
0.00 [-0.44,
25.18 [-57.387, -41 -0.10 [-0.40, Std. Mean Differr
IV, Random,
0.00 [-0.3 -0.310 [-0.40, -0.01 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, -0.10 [-0.40, | 5% CI
0.20]
0.44]
6.49]
0.19]
ence
<u>95% CI</u>
39,0.39]
94,0.18]
55,0.55]
1185.29]
56,0.45]
9,-0.37]
52,0.26]
-712.19] | 2019
2022
2023
2023
2023
2029
2019
2020
2021
2021
2022
2022
2023
 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean D | h, 95% Cl
25 50
Favours [SAPB] |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Heterogeneity: Tau* =
Test for overall effect 2
Study or Subgroup
Wang 2019 [28]
Eldernrdash 2019 [28]
Eldernrdash 2019 [28]
Shrivastava 2021 [31]
Nyima 2023 [30]
Bedewy 2023 [32]
Total (95% CI)
 | 3.1
0.64 (
1.88 0.
0.00; Chi ^P
Z = 0.70 (P
Mean
3.3
2.34
1.011
1.6
0.5
1.95
4.3598
 | 1.1 5
0.76 4
001 4
= 0.40, dt
= 0.48)
ESPB 50
1.1
2.65
0.099
0.001
0.685
0.681
0.76
0.001
1.9946
 | 50 3
10 0.10 2
10 2
10 7
10 7
1 | an 5
3.3
64 0.7
38 0.00
= 0.53);
Mean
3.3
3.64
1.011
1.28
2.26
0.64
2.805
2.9281 | SD Tota 1 50 76 41 01 41 91 91 1 ² = 0% 50 SAPB 50 1.1 3.93 0.009 0.001 0.716 0.55 0.76 0.001 1.4361 1.4361
 | 0 55.
0 44.
0 0.
0 100.
Total 50
25
25
25
25
25
30
20
40
40
20
275 | ght
4%
6%
0% -4
0%
-4
14.5%
14.3%
14.3%
14.3%
14.3%
14.4%
0.0% | IV, Random, 9 -0.19 [0.56,
0.00 [0.04,
55.18 [-57.387, -41 -0.10 [-0.40, Std. Mean Differt
IV, Random,
0.00 [0.3
-0.38 [0.9
0.00 [0.5]
-0.38 [1.0]
-0.06 [0.5]
-1.03 [1.6]
-0.48 [0.6]
-0.48 [0.6]
 | 5% CI
0.20] :
0.44] :
6.49] :
0.19]
ence
.95% CI
95% CI | 2019
2022
2023
Year
2019
2020
2021
2022
2022
2022
2022
2023
2023 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean D | h, 95% Cl
25 50
Favours [SAPB] |
| Wang 2019 [28] Ahuja 2022 [31] Nyima 2023 [30] Total (95% CI) Heterogeneilty: Tau* = Study of Subgroup Wang 2019 [28] Elderndash 2019 [26] Elderndash 2019 [26] Shmisstava 2021 [24] Jiang 2021 [29] Sagar 2022 [23] Ahuja 2022 [30] Bedewy 2023 [32]
 | 3.1
0.64 (
1.88 0.
0.00; ChP
Z = 0.70 (P
Mean
3.3
2.34
1.011
2
1.24
1.6
0.5
1.95
4.3598

 | 1.1 5
0.76 4
001 4
= 0.40, dt
= 0.40, dt
= 0.48)
ESPB
SD
1.1
2.65
0.089
0.001
0.685
0.681
0.76
0.001
1.9946
260.81, dt
 | 50 3
10 0.10 2
10 2
10 7
10 7
1 | an 5
3.3
64 0.7
38 0.00
= 0.53);
Mean
3.3
3.64
1.011
1.28
2.26
0.64
2.805
2.9281 | SD Tota 1 50 76 41 01 41 91 91 1 ² = 0% 50 SAPB 50 1.1 3.93 0.009 0.001 0.716 0.55 0.76 0.001 1.4361 1.4361
 | 0 55.
0 44.
0 0.
0 100.
Total 50
25
25
25
25
25
30
20
40
40
20
275 | ght
4%
6%
0% -49
.0%
14.5%
14.3%
14.3%
14.3%
14.3%
14.3%
14.1% | IV, Random, 29
-0.191058,
0.001044,
9518[-573.87.41
-0.101040,
Std. Mean Differt
IV,
Random,
0.00103
-0.3109
0.00103
-0.3109
0.00103
-0.310
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0 | 5% CI
0.20] :
0.44] :
6.49] :
0.19]
ence
.95% CI
95% CI | 2019
2022
2023
Year
2019
2020
2021
2022
2022
2022
2022
2023
2023 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean C
IV, Randor | 25 50
Favours (SAPB)
Miference
a, 55% Cl |
| Wang 2019 [28] Ahuja 2022 [31] Nyima 2023 [30] Total (95% Cl) Heterogeneilty, Tau* = 1 Study or Subgroup Wang 2019 [28] Eldemidash 2019 [28] Eldemidash 2019 [28] Eldemidash 2019 [28] Shinya stava 2021 [24] Jiang 2021 [29] Sagar 2022 [23] Anuja 2022 [23] Bedewy 2023 [32] Total (95% Cl)
 | 3.1
0.64 (
1.88 0.
0.00; ChP
Z = 0.70 (P
Mean
3.3
2.34
1.011
2
1.24
1.6
0.5
1.95
4.3598

 | 1.1 5
0.76 4
001 4
= 0.40, dt
= 0.40, dt
= 0.48)
ESPB
SD
1.1
2.65
0.089
0.001
0.685
0.681
0.76
0.001
1.9946
260.81, dt
 | 50 3
10 0.10 2
10 2
10 7
10 7
1 | an <u>5</u>
3.3
64 0.0
5
Mean
3.3
3.3
3.3
3.3
3.3
3.3
3.3
3. | SD Tota 1 50 76 41 01 41 91 91 1 ² = 0% 50 SAPB 50 1.1 3.93 0.009 0.001 0.716 0.55 0.76 0.001 1.4361 1.4361
 | 0 55.
0 44.
0 0.
0 100.
Total 50
25
25
25
25
25
30
20
40
40
20
275 | ght
4%
6%
0% -49
.0%
14.5%
14.3%
14.3%
14.3%
14.3%
14.3%
14.1% | IV, Random, 29
-0.191058,
0.001044,
9518[-573.87.41
-0.101040,
Std. Mean Differt
IV,
Random,
0.00103
-0.3109
0.00103
-0.3109
0.00103
-0.310
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.00103
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0010
-0.0 | 5% CI
0.20]
0.44]
6.49]
0.19]
ence
9.95% CI
0.19]
ence
9.95% CI
0.19]
6.0.45]
9.0.39
9.0.37
9.0.26
9.0.27
12.19
16, 1.45]
44, 1.13] | 2019
2022
2023
Year
2019
2020
2021
2022
2022
2022
2022
2023
2023 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean
IV, Randon
-4 -2 0
Favours [ESPB] | a, 95% CI |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Heterogeneity. Tau ^{ar} = 1
Test for overall effect 2
Study or Subgroup
Elderndash 2019 [26]
Elderndash 2019 [26]
Elderndash 2019 [26]
Sagar 2022 [33]
Ahuja 2022 [31]
Nyima 2023 [32]
Bedewy 2023 [32]
Total (95% CI)
Heterogeneity. Tau ^a = 2
Test for overall effect 2
Study or Subgroup
 | 3.1
0.64 (
1.88 0.
0.00; ChP
Z = 0.70 (P
Mean
3.3
2.34
1.011
2
1.24
1.6
0.5
1.95
4.3598
.94; ChP =
0.24 (P =
Mean
 | 1.1 6
0.76 4
001 4
= 0.40, dt
= 0.48)
ESPB
5D
0.001
1.1 2.65
0.009
0.001
1.946
0.001
1.9946
260.81, dt
0.81)
ESPB
5D
 | 50 3
10 0.1
10 2.2
30
10 1.2
30
10 2.2
30
10 2.2
50
25
25
30
20
20
20
20
20
20
20
20
20
2 | an <u>5</u>
3.3
64 0.7
38 0.00
= 0.53);
 | SD Tota 1 50 76 41 91 41 91 91 92 9% 1.1 3.93 3.93 0.001 0.716 0.089 0.001 0.76 0.55 0.76 0.001 1.4361 1.4361 1.1 91); P= 9 SAPB SD SAPB | 0 55.
0 44.
0 0.
0 100.
Total
50
25
25
25
30
20
20
20
20
20
275
7% | ght
4%
6%
6%
0% -41
14.5%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.4%
100.0%
Weight
 | W, Random, 9 -0.19 [0.56, 0.00] (0.44, 55.18 [-57.3.87, -41 -0.10 [-0.40, 55.18 [-57.3.87, -41 -0.10 [-0.40, 0.00] (0.10, 0.00, | 5% CI
0.20] :
0.44] :
6.49] :
0.19]
ence
ence
95% CI
0.19]
ence
1055, 055
1185 29]
44, 018]
55, 055
1185 29]
44, 018]
55, 055
1185 29]
44, 018]
55, 055
1185 29]
44, 113]
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence
ence | 2019
2022
2023
2023
2023
2019
2019
2021
2021
2021
2022
2022
2023
2023
2023
 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean I
IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB] | 25 50
Favours (SAPB)
Miference
a, 55% Cl |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Heterogeneity Tau* =
Test for overall effect 2
Study or Subgroup
Wang 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [28]
Sagar 2022 [31]
Nyima 2023 [20]
Bedewy 2023 [32]
Total (95% CI)
Heterogeneity: Tau* = 2
Study or Subgroup
Wang 2019 [28]
 | 3.1
0.64 (
1.88 0.
0.00; Chi ^p
Z = 0.70 (P
Mean
3.3
2.34
1.011
1.6
0.5
1.95
4.3598
94; Chi ^p =
0.24 (P =
 | 1.1 4
0.76 4
001 4
= 0.40, d
= 0.40, d
= 0.48)
ESPB
50
0.681
0.76
0.001
0.685
0.681
0.76
0.001
1.9946
260.81, d
0.81)
ESPB
50
1.1
 | 50 3
10 0)
10 2
10 2
10
10 2
10 2
10
10 2
10
10 2
10
10
10
10
10
10
10
10
10
10 | an 5
3.3
64 0.7
38 0.00
= 0.53);
5
<u>Mean</u>
3.3
64
1.011
1
1.28
0.64
2.255
0.64
2.9281
< 0.0000 | SD Tota
1 55
76 44
11 44
99
14 99
14 99
14 99
14 99
14 99
14 99
14 99
14 99
14 99
13
93
0.089
0.001
1.4361
0.716
0.076
0.001
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4 | 0 55.
0 44.
0 0.
0 100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
10 | ght
4%
6%
0% -4
14.5%
14.3%
14.3%
0.0%
14.3%
14.1%
10.0%
14.1%
100.0% | IV, Random, 9 -0.19 [c.058, 0.00 [c.0.44, 0.95] 95.18 [c.57.3.87, -41] -0.10 [c.0.40, 0.95] Std. Mean Differt IV, Random 90.4 29 [73.29, 1 -0.08 [c.0, 0.00 [c.0, 0.0
 | 5% CI
0.201 :
6.491 :
0.191 :
0.191 :
0.191 :
0.191 :
0.39, 0.39
94, 0.181 :
51.05.291 :
56, 0.451 :
51.05.291 :
56, 0.451 :
11.65.291 :
56, 0.451 :
11.65.291 :
56, 0.451 :
11.65.291 :
56, 0.451 :
11.65.291 :
1 | 2019
2022
2023
2023
2029
2029
2029
2020
2021
2022
2022
2022 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean I
IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB] | 25 50
Favours [SAPB]
Miterence
n, 95% Cl |
| Wang 2019 [28] Ahuja 2022 [31] Nyima 2023 [30] Total (95% CI) Helsrogeneity, Tau* = 1 Test for overall effect 2 Study or Subgroup Wang 2019 [28] Eldemrdash 2019 [26] Elsabeenv 2020 [27] Shnya 2021 [28] Helsrogeneity, Tau* = 2 Show 2021 [29] Bedewy 2023 [20] Bedewy 2023 [20] Helsrogeneity, Tau* = 2 Test for overall effect Z Study or Subgroup Wang 2019 [28] Eldemrdash 2019 [28] Eldemrdash 2021 [29] Study or Subgroup
 | 3.1
0.64 (
1.88 0.
0.00; Ch ^P
Z = 0.70 (P
Mean
3.3
2.34
1.011
2
1.24
1.66
0.5
1.95
4.3598
94; Ch ^P =
0.24 (P
=
Mean
3.4
3.4
3.4
3.5
4.3598
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95 | 1.1 1.1 1.76 4 0001 4 9 1 9 = 0.40, di 9 = 0.40, di 1.1 2.65 1.1 2.65 0.089 0.001 0.681 0.069 0.001 1.9846 260.81, di 0.081 ESPB SD 1.1 1.314
 | 50 3
10 0.
10 2
10 7
10 7
10
10 7
10 7
1 | an <u>5</u>
3.3
64 0.7
38 0.00
= 0.53);
5
Mean
3.3
3.64
3.3
3.64
5
Mean
4.0000
4.0000
4.00000
Mean
3.4
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.00000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.000000
4.0000000
4.0000000
4.000000
4.000000
4.000000
4.000000
4.0000000
4.0000000
4.0000000
4.0000000
4.0000000
4.00000000
4.00000000
4.0000000000
 | SD Tota
1 55
76 4/
11 4/
99
99
99
99
99
90
11 1
3.93
3.93
0.001
1.11
3.93
0.009
0.001
0.716
0.055
0.766
0.055
0.766
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1. | 0 55.
0 44.
0 0.
0 100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
10 | ght
4%
6%
0% -4{
14.5%
14.3%
0.0%
14.3%
0.0%
14.3%
0.0%
14.4%
100.0%
14.14
14.15
100.0% | N, Random, 9 -0.19 [-0.56, 0.00] (-0.44, 0.00] (-0.44, 0.55) 55.18 [-57.3.87, -41] (-0.40, 0.55) -0.10 [-0.40, 0.00] (-0.40, 0.00] (-0.40, 0.00] (-0.40, 0.00] (-0.40, 0.00] (-0.40, 0.00] (-0.40, 0.00] (-0.40, 0.00] (-0.40, 0.00]
(-0.40, 0.00] (-0.40 | 5% CI
0.201 :
0.441 :
6.491 :
0.191 :
0.193 :
0.193 :
0.193 :
0.193 :
0.0191 :
0.193 :
0.0191 | 2019
2022
2023
2023
2023
2019
2019
2020
2021
2021
2022
2022
2023
2023
2023 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean I
IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB] | 25 50
Favours [SAPB]
Miterence
n, 95% Cl |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Heterogeneity Tau* =
Test for overall effect 2
Study or Subgroup
Wang 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [28]
Sagar 2022 [31]
Nyima 2023 [20]
Bedewy 2023 [32]
Total (95% CI)
Heterogeneity: Tau* = 2
Study or Subgroup
Wang 2019 [28]
 | 3.1
0.64 (
1.88 0.
0.00; ChP
Z = 0.70 (P
Mean
3.3
2.34
1.011
2
1.24
1.66
0.5
1.95
4.3598
9.4; ChP =
= 0.24 (P
=
Mean
3.4
3.2
2.24
1.65
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95
1.95 | 1.1 4
0.76 4
001 4
= 0.40, d
= 0.40, d
= 0.48)
ESPB
50
0.681
0.76
0.001
0.685
0.681
0.76
0.001
1.9946
260.81, d
0.81)
ESPB
50
1.1
 | 50 3
10 0)
10 2
10 2
10
10 2
10 2
10
10 2
10
10 2
10
10
10
10
10
10
10
10
10
10 | an <u>5</u>
3.3
3.3
8
8
8
8
8
8
8
8
8
8
8
8
8
 | SD Tota
1 55
76 44
11 44
99
14 99
14 99
14 99
14 99
14 99
14 99
14 99
14 99
14 99
13 93
0.089
0.001
1.4361
0.716
0.076
0.001
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4361
1.4 | 0 55.
0 44.
0 0.
0 100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
10 | ght
4%
6%
0% -4
14.5%
14.3%
14.3%
0.0%
14.3%
14.1%
10.0%
14.1%
100.0% | IV, Random, 9 -0.19 [c.58,
0.00 [c.0.44, 0.00 [c.0.44, 0.00 [c.0.44, 0.00 [c.0.44, 0.00 [c.0.40, | 5% CI
0.201 ::
0.44] :
6.49] :
0.19] :
ence
 | Year 2019 2023 2019 2019 2020 2019 2020 2021 2022 2023 2024 2025 2020 2021 2022 2023 2024 30 30 30 30 30 30 30 30 30 30 30 30 < | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean I
IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB] | 25 50
Favours [SAPB]
Miterence
n, 95% Cl |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Heterogenety: Tuu* = 1
Test for overall effect 2
Study of Subgroup
Elderndash 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [29]
Sagar 2022 [31]
Nyima 2023 [31]
Nyima 2023 [32]
Total (95% CI)
Heterogenety: Tau* = 2
Study of Subgroup
Wang 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [29]
Elderndash 2019 [29]
Elderndash 2019 [29]
Elderndash 2019 [29]
Elderndash 2019 [29]
Elderndash 2019 [29]
 | 3.1
0.64 (
1.88 0
0.00; ChP
Z = 0.70 (P
Mean
3.3
2.34
1.011
2
1.24
1.6
0.5
1.95
4.3598
9.94; ChP
= 0.24
(P
=
Mean
3.4
3.2
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.04
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1.05
1 | 1.1 1 1.7.76 4 0.001 4 9 9 9 9 9 9 9 9 9 11 2.65 0.069 0.001 0.681 0.061 1.946 2.60.81, d. 0.611 1.946 SD 3.14 0.6227 0.021 1.1 3.14 1 0.6227 0.021
 | 50 3
10 0.10 2
10 2
1 | an <u>5</u>
3.3
3.3
8 0.00
= 0.53);
5
<u>Mean</u>
3.3
4
1.011
1
1.28
2.25
3.64
1.011
1
1.28
2.9281
< 0.0000
 | SD Tota 1 5/5 41 91 1 1 91 1 1 92 1 1 93 0.089 0.001 0.716 0.76 0.001 0.718 0.76 0.001 1.1331 1.363 3.3 0.5916 5.0 0.001 1.1 3.93 0.5916 | 0 55.
0 44.
0 0.
0 100.
Total
50
25
25
25
25
25
20
40
20
20
20
20
20
20
20
20
20
2 | ght
4%
6%
0% -41
14.5%
14.3%
14.3%
14.3%
0.0%
14.1%
14.4%
0.0%
14.1%
100.0%
Weight
12.5%
12.5% | IV, Random, 9 -0.19 [c.58, 0.00 [c.0.44, 0.95] 0.010 [c.0.40, 0.95] 95.18 [c.57.3.87, -41] -0.10 [c.0.40, 0.95] Std. Mean Differr IV, Random, 0.00 [c.0.40, 0.96] -0.00 [c.0.40, 0.96]
904.29 [703.28, 1] -0.06 [c.0.40, 0.96] -0.06 [c.0.40, 0.96] -0.46, 75 [s981.31, -0.06 [c.0.40, 0.97] -0.46, 75 [s981.31, -0.016 [c.1.40] -0.16 [c.1.40] Std. Mean Differ t/V, Random 0.00 [c.0.40, 0.97] -0.48 [c.0.40, 0.97] -0.48 [c.0.40, 0.97] -0.18 [c.0.40, 0.97] -0.18 [c.0.40, 0.97] -0.08 [c.0.40, 0.97] -0.18 [c.0.40, 0.97] -0.08 [c.0.40, 0.97] -0.08 [c.0.40, 0.97] -0.18 [c.0.40, 0.97] -0.08 [c.0.40, 0.97] -0.08 [c.0.40, 0.97] | 5% CI
0.20) :
0.44) :
6.49) :
0.19]
ence
9.95% CI
6.49 :
0.19]
94.019]
95.055% CI
105.29
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
94.019]
95.045]
95.045]
94.019]
95.045]
95.045]
94.045]
95.045]
94.045]
94.045]
95.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
94.045]
95.045]
94.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]
95.045]95.045]
95.045]
95.045]
95.045]
95.045]95.045]
95.045]
95.045]95.045]
95.045]
95.045]95.045]
95.045]
95.045]95.045]
95.045]
95.045]
95.045]95.045]
95.045]
95.045]95.045]
95.045]
95.045]95.045]
95.045]95.045]
95.045]95.05]
95.05]
95.05]95.05]
95.05]
95.05]95.05]
95.05]95.05]
95.05]95.05]
95.05]95.05]
95.05]95.05]
95.0 | 2019 2022 2023 2019 2019 2020 2020 2021 2020 2021 2022 2023 2020 2021 2022 2023 2023 2023 2023 2023 2023 2023 2023 2023 2023 2023 2023 2023 2023 2023 2023 2023 2024 2025 2020 2021 2022 2023 2024 2025 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean I
IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB] | 25 50
Favours [SAPB]
Miterence
n, 95% Cl |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Heterogeneity, Tau* = 1
Test for overall effect 2
Study or Subgroup
Elderndash 2019 [26]
Elderndash 2019 [26]
Elderndash 2019 [27]
Bhrvastava 2022 [31]
Ahuja 2022 [31]
Nyima 2023 [32]
Heterogeneity, Tau* = 2
Test for overall effect Z
Study or Subgroup
Wang 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [29]
Britastava 2022 [33]
 | $\begin{array}{c} 3.1 & (\ 1.88 & 0) \\ 0 & 0.0 & (\ h^{\mu} {}^{\mu} {}^{\mu} {}^{\mu} {}^{2$
 | 1.1 1.1 1.7.76 4 0.001 4 9 = = 0.40, dt = 0.40, dt = 0.40, dt = 0.40, dt 26.5 0.681 0.061 1.1 1.946 0.76 0.001 1.946 SD 0.81 1.1 3.14 0.6227 0.031 0.733 0.733
 | 50 3
10 0.
10 2.
10 | an <u>5</u>
3.3
3.3
3.3
3.8
4.0
3.8
3.0
4.0
3.3
3.6
4
1.011
1
1.2
8
2.25
2.9281
2.9281
2.9281
2.9281
2.9281
2.9281
2.9281
2.935
2.9281
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.935
2.9355
2.9355
2.9355
2.9355
2.9355
2.9355
2.9355
2.9355
2.93555
2.93555
2.93555555555555555555555555555555555555 | SD Tota
SD Tota
1 5576 41
99
976 41
99
978
50
1.1
3.933
0.089
0.001
0.716
0.055
0.766
0.001
1.1
1.391
1.1
1.393
0.089
0.001
0.716
50
0.055
0.766
1.1
1.393
0.089
0.001
0.716
50
0.055
0.766
0.001
1.1
1.393
0.059
0.055
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057 | 0 55.
0 44.
0 0.
0 100.
Total
50
25
25
25
25
25
20
40
20
20
40
20
275
7%
Total
50
20
20
40.
20
20
40.
20
20
20
20
20
20
20
20
20
20 | ght
4%,
6%,
0%, -41
.0%
.0%
.14.3%,
14.3%,
14.3%,
14.3%,
14.3%,
14.3%,
14.3%,
14.3%,
14.3%,
14.3%,
14.3%,
12.5%,
12.5%,
12.5%,
12.5%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.3%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
12.5%,
1 | W, Random, 9 -0.19 [-0.56,
0.00](-0.44,
55.18 [-57.3.87, -41 -0.10 [-0.40,
55.18 [-57.3.87, -41 -0.10 [-0.40,
0.00 [-0.3]
-0.00 [-0.3]
-0.00 [-0.3]
-0.06 [-0.5]
-0.016 [-0.40,
-0.18 [-0.6]
-0.16 [-1.4] Std. Mean Different
(V, Random
-0.16 [-1.4] Std. Mean Different
(V, Random
-0.16 [-1.4] Std. Mean Different
(V, Random
-0.16 [-1.4] Std. Mean Different
(V, Random
-0.00 [-0]
-0.00 [-0] -0.00 [-0]
-0.00 [-0]
 | 5% C1
0.20) :
0.44) :
0.44) :
0.44) :
0.19)
0.39% C1
0.39% C1
0.39% C3
0.39% C3
0.39% C3
0.39% C3
0.39% C3
0.39% C3
0.39% C3
0.5% C3
0 | Year 2019 2019 2019 2019 2019 2019 2019 2019 2020 2021 2022 2023 2021 2022 2023 2023 2023 2023 2029 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2029 2029 2029 2029 2029 20203 2019 5 2019 10 10 10 10 10 10 10 10 10 10 10 < | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean I
IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB] | 25 50
Favours [SAPB]
Miterence
n, 95% Cl |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Hoterogeneity: Tuu* = 1
Test for overall effect 2
Study of Subgroup
Elderndash 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [29]
Sagar 2022 [33]
Ahuja 2022 [31]
Nyima 2023 [32]
Total (95% CI)
Heterogeneity: Tau* = 2
Test for overall effect 2
Study of Subgroup
Wang 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [29]
Shrhrastava 2022 [31] | 3.1
0.64 (1
1.88 0.
0.00, Chi ⁿ (1
2 = 0.70 (P
Mean
3.3
2.34
1.011
2.124
1.61
9.55
1.95
4.3590
9.43 (Chi ⁿ = 0.24 (P = 0 | 1.1 1.1 1.7.76 4 0.001 4 9 9 9 9 9 9 9 9 9 9 9 9 11 2.65 0.089 0.001 0.681 0.001 0.001 1.946 260.81, d 0.001 1.946 SD 1.1 9.46 9.001 1.1 9.001 1.1 9.001 1.1 9.001 1.1 9.001 1.1 9.001 1.1 9.001 1.1 9.001 1.1 9.001 1.1 9.001 1.1 9.001 1.1 9.001 1.1 9.001 1.1 9.001 1.1 9.001 1.1 9.001 1.1 9.001 1.1 <td>50 3
10 0.10 2
10 2
1</td> <td>an <u>\$</u>
3.3
64 0.0
38 0.00
\$
S
Mean
3.3
3.64
1.2
8
2.9281
< 0.0000
Mean
3.4
3.64
1.2
8
5.2
9.281
< 0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
1.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.2815</td> <td>SD Tota 1 157 44 99 9" 9% AAPB 50 1.1 3.93 3.0.089 0.001 1.1 3.93 3.91 1.1 0.011 1.4361 11.1 3.83 3.0.5916 0.001 1.1 3.83 3.05916 0.001 0.021 0.021</td> <td>0 55.
0 44.
0 0.
0 100.
Total
50
25
25
25
25
25
20
40
20
20
20
20
20
20
20
20
20
2</td> <td>ght
4%
6%
0% -41
0%
14.3%
14.3%
14.3%
0.0%
14.3%
0.0%
14.4%
0.0%
14.4%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%</td> <td>IV, Random, 9 -0.19 [c.58, 0.00 [c.0.44, 0.95] 0.010 [c.0.40, 0.95] 95.18 [c.57.3.87, -41] -0.10 [c.0.40, 0.95] Std. Mean Differt IV, Random 0.00 [c.0.41, 0.95] 904 29 [763.29, 1.000 [c.0.40, 0.00 [c.0.40, 0.</td> <td>5% CI
0.201 :
0.441 :
0.451 :</td> <td>2019
2022
2023
2023
2029
2019
2019
2020
2020
2020
2020
2022
2022</td> <td>IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean I
IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]</td> <td>25 50
Favours [SAPB]
Miterence
n, 95% Cl</td> | 50 3
10 0.10 2
10 2
1 | an <u>\$</u>
3.3
64 0.0
38 0.00
\$
S
Mean
3.3
3.64
1.2
8
2.9281
< 0.0000
Mean
3.4
3.64
1.2
8
5.2
9.281
< 0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
1.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.2815 | SD Tota 1 157 44 99 9" 9% AAPB 50 1.1 3.93 3.0.089 0.001 1.1 3.93 3.91 1.1 0.011 1.4361 11.1 3.83 3.0.5916 0.001 1.1 3.83 3.05916 0.001 0.021 0.021 | 0 55.
0 44.
0 0.
0 100.
Total
50
25
25
25
25
25
20
40
20
20
20
20
20
20
20
20
20
2 | ght
4%
6%
0% -41
0%
14.3%
14.3%
14.3%
0.0%
14.3%
0.0%
14.4%
0.0%
14.4%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5% | IV, Random, 9 -0.19 [c.58, 0.00 [c.0.44, 0.95] 0.010 [c.0.40, 0.95] 95.18 [c.57.3.87, -41] -0.10 [c.0.40, 0.95] Std. Mean Differt IV, Random 0.00 [c.0.41, 0.95] 904 29 [763.29, 1.000 [c.0.40, 0.00 [c.0.40, 0. | 5% CI
0.201 :
0.441 :
0.451 : | 2019
2022
2023
2023
2029
2019
2019
2020
2020
2020
2020
2022
2022 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean I
IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB] | 25 50
Favours [SAPB]
Miterence
n, 95% Cl |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Heterogeneity, Tau* = 1
Test for overall effect 2
Study or Subgroup
Elderndash 2019 [26]
Elderndash 2019 [26]
Elderndash 2019 [27]
Bhrvastava 2022 [31]
Ahuja 2022 [31]
Nyima 2023 [32]
Heterogeneity, Tau* = 2
Test for overall effect Z
Study or Subgroup
Wang 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [28]
Elderndash 2019 [29]
Britastava 2022 [33]
 | 3.1
0.64 (1
1.88 0.
0.00, Chi ⁿ (1
2 = 0.70 (P
Mean
3.3
2.34
1.011
2.124
1.61
9.55
1.95
4.3590
9.43 (Chi ⁿ = 0.24 (P = 0 | 1.1 1.1 1.7.76 4 0.001 4 9 9 9 1.1 2.85 50 1.1 2.85 0.089 0.001 0.685 0.001 0.685 0.76 0.081 1.1 1.946 0.861 1.00.827 0.767 0.001 0.772 0.001 0.001 0.021 1.1 3.14 1.0 0.027 0.001 0.733 0.077 0.7978 0.7978

 | 50 3
10 0.10 2
10 2
10
10 | an <u>\$</u>
3.3
64 0.0
38 0.00
\$
S
Mean
3.3
3.64
1.2
8
2.9281
< 0.0000
Mean
3.4
3.64
1.2
8
5.2
9.281
< 0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
4
0.0000
Mean
3.4
1.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.281
5.2815 | SD Tota
SD Tota
1 5576 41
99
976 41
99
978 50
1.1
3.933
0.089
0.001
0.716
0.055
0.766
0.001
1.1
1.391
1.1
1.393
0.089
0.001
0.716
50
0.055
0.766
1.1
1.393
0.089
0.001
0.716
50
0.055
0.766
0.001
1.1
1.393
0.059
0.055
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.055
0.056
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
0.057
 | 0 55.
44.
0 0.
0 100.
0 100.
Total
50
25
25
25
25
30
20
40
40
20
275
7%
Total
50
20
20
20
20
20
20
20
20
20
2 | ght
4%,
6%,
0%, -41
0%,
14,5%,
14,3%,
0,0%,
14,3%,
0,0%,
14,3%,
0,0%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12 | IV, Random, 9 -0.19 [c.58, 0.00 [c.0.44, 0.95] 0.010 [c.0.40, 0.95] 95.18 [c.57.3.87, -41] -0.10 [c.0.40, 0.95] Std. Mean Differt IV, Random 0.00 [c.0.41, 0.95] 904 29 [763.29, 1.000 [c.0.40, 0.00 [c.0.40, 0. | 5% CI
0.20) :
0.44) :
0.44) :
0.44) :
0.44] :
0.45] : | Year 2019 2022 2023 2019 2019 2019 2019 2019 2019 2020 2021 2022 2023 4 2022 2023 4 4 202 2023 4
 4 4 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean I
IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB] | 25 50
Favours [SAPB]
Miterence
n, 95% Cl |
| Wang 2019 [28] Ahuja 2022 [31] Nyima 2023 [30] Total (95% CI) Heterogeneity, Tau* = i
Test for overall effect 2 Study or Subgroup Wang 2019 [28] Eldemrdash 2019 [26] Eldemrdash 2019 [26] Eldemrdash 2019 [26] Bedewy 2021 [21] Nyima 2023 [20] Bedewy 2023 [21] Heterogeneity, Tau* = 2 Total (95% CI) Heterogeneity, Tau* = 2 Test for overall effect Z Study or Subgroup Wang 2019 [28] Eldemrdash 2019 [28] Bayar 2022 [23] Ahuja 2022 [31] Bedewy 2023 [22]
 | $\begin{array}{c} 3.1 \\ 0.64 & (i) \\ 1.88 & 0. \\ 0.00, Chi^{\mu} \\ \hline \\ $
 | 1.1 1.1 1.7.76 4 0001 4 9 9 9 1.1 2.85 50 1.1 2.85 0.089 0.001 0.685 0.001 0.685 0.76 0.081 1.1 1.946 0.861 1.00.827 0.767 0.001 0.767 0.001 0.773 0.001 0.733 0.7978 0.7978
 | 50 3
10 0.
10 2
10 2
10
10 2
10 2
10
10 2
10 2
10 2
10
10 2
10
10
10
10
1 | an <u>5</u>
3.3
64 0.1
38 0.00
S
Mean
3.3
3.64
1.011
1.2
0.64
2.25
2.9281
Mean
3.4
3.64
1.011
1.2
85
2.9281
Mean
3.4
3.64
2.25
0.0000
Mean
3.4
3.64
2.285
0.0000
Mean
3.4
3.64
0.0000
Mean
3.4
3.64
0.0000
Mean
3.4
3.64
0.0000
Mean
3.4
3.64
0.0000
Mean
3.4
3.64
0.0000
Mean
3.4
3.64
0.0000
Mean
3.4
3.64
0.0000
Mean
3.4
3.64
0.0000
Mean
3.4
3.64
0.0000
Mean
3.4
3.64
0.0000
Mean
3.4
3.64
0.0000
Mean
3.4
3.64
0.0000
Mean
3.4
3.64
0.0000
Mean
3.4
3.64
0.0000
Mean
3.4
3.64
3.64
0.64
0.0000
Mean
3.4
3.64
0.64
0.0000
Mean
3.4
3.64
2.280
0.6000
Mean
3.4
3.64
2.280
0.6000
Mean
3.4
3.64
2.280
0.6000
Mean
3.4
3.64
2.280
0.6000
Mean
3.4
3.64
2.280
0.6000
Mean
3.4
3.64
2.280
0.6000
Mean
3.4
3.64
2.280
0.6000
Mean
3.4
3.64
2.280
0.6000
Mean
3.4
3.64
2.2800
0.6000
Mean
3.4
3.64
2.2800
0.6000
Mean
3.4
3.64
2.2800
0.60000000
Mean
3.4
3.4
3.64
2.2800
0.64
0.6000000
Mean
3.64
3.64
1.61
1.28000000000000000000000000000000000000 | SD Tota 1 1 5 76 41 9 99 1 44 99 12 0% 1 1.1 3.93 0.001 0.011 1.4361 0.55 0.76 0.011 1.4361 3.33 3.33 0.591 5.010 0.001 1.13962 1.11 3.933 3.33 3.900 0.551 0.010 0.745 0.001 0.745 0.010 0.745 0.010
 | 0 55.
44.
0 0.
0 100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100. | ght
4%,
6%,
0%, -41
0%,
14,5%,
14,3%,
0,0%,
14,3%,
0,0%,
14,3%,
0,0%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
12,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12 | IV, Random, 9 -0.19 [0.58,
0.00 [0.44,
9518] [573.87, 41 -0.10 [0.40, Std. Mean Differt
IV, Random,
0.00 [0.3] -0.10 [0.40, 904 29 [73.28, 1 -0.06 [0.5,
-1.03 [1.6] -0.16 [-1.40, -0.16 [-1.40, -0.17 [0.40, -0.18 [0.1,
-0.16 [-1.40, Std. Mean Differt
IV, Random,
0.00 [0, -0.18 [0,
-0.00 [0, -0.20
 | 5% C1
0.20) :
0.44) :
0.44) :
0.44) :
0.44] :
0.44] :
0.44] :
0.44] :
0.44] :
0.44] :
0.44] :
0.35% C2
0.35% C2
0.35% C2
0.45% C2
0.44% C2
0.45% C2 | Year 2019 2022 2023 2019 2019 2019 2019 2019 2019 2020 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean I
IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB] | 25 50
Favours [SAPB]
Miterence
n, 95% Cl |
| Wang 2019 [28] Ahuja 2022 [31] Nyima 2023 [30] Total (95% CI) Heterogeneity, Tau* = 1 Test for overall effect 2 Study or Subgroup Wang 2019 [28] Elderndash 2019 [26] Elderndash 2019 [26] Elderndash 2019 [26] Bady 2022 [27] Shraya 2021 [24] Anuja 2022 [21] Nyima 2023 [20] Bedewy 2023 [22] Total (95% CI) Eldernrasta 2019 [26] Eldernrasta 2019 [27] Shrastava 2021 [29] Shrastava 2022 [21] Wang 2019 [28] Eldernrastava 2019 [28] Bagar 2022 [23] Ahuja 2022 [23] Nyima 2023 [20] Nyima 2023 [20] Nyima 2023 [20] Nyima 2023 [20] Heterogeneity, Tau* = 1
 | 31
0.64 (1.88 0.
0.00, Chi ^m = 2 = 0.70
(P
Mean
33
234
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
10 | 1.1 4 0.76 4 0.076 4 0.076 4 0.001 4 dd
 | 50 3
10 0)
10 2
10 2
10
10 2
10 2
10
10 2
10
10 2
10
10
10
10
10
10
10
10
10
10 | an <u>\$</u>
3.3
64 0.0
38 0.00
S
Mean
3.3
3.64
2.25
0.0000
Mean
3.64
2.9281
Mean
3.64
3.64
2.905
2.9281
Mean
3.64
2.905
2.9281
Mean
3.64
2.2505
2.9281
Mean
3.64
2.2505
2.9281
Mean
3.64
3.64
2.2505
2.9281
Mean
3.64
3.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.555
0.555
0.555
0.555
0.555
0.555000
0.55500000000
 | D Totate 1 55 14 1 57 14 9 9 9 11 14 9 9 9 9 11 14 9 11 14 9 11 19 9 10 13 3.93 0.089 0.001 0.715 0.001 0.715 0.001 1.1 1.93 3 3 3 3 3 3 3 0.745 0.765 0.765 0.745 0.786 0.786 0.745 0.786 0.786 | 0 55.
0 44.
0 0.
0 100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
10 | ght
4%,
6%,
0%, -41
0%,
14,5%,
14,3%,
0,0%,
14,3%,
14,3%,
0,0%,
14,3%,
14,3%,
14,1%,
14,1%,
14,1%,
14,1%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
1 | IV, Random, 9 -0.19 [0.58,
0.00
[0.44,
9518] [573.87, -41 -0.10 [0.40, Std. Mean Differt
IV, Random,
0.00 [0.3] -0.10 [0.40, 91.8 [0.73, 28, 1 -0.6 [0.5,
-1.03 [1.6] -0.16 [0.40, -0.17 [0.40, -0.18 [0.0,
-0.06 [0.5,
-1.03 [1.6] -0.18 [0.1,
-0.16 [1.4] Std. Mean Differt
IV, Randor Std. Mean Differt
-0.06 [0.0, 0.00 [0,
-0.00 [0, 0.00 [0,
-0.00 [0, 0.00 [0,
-0.00 [0, 0.00 [0 | 5% C1
0.20) :
0.44) :
0.44) :
0.44) :
0.44] :
0.44] :
0.44] :
0.44] :
0.44] :
0.44] :
0.44] :
0.35% C2
0.35% C2
0.35% C2
0.45% C2
0.44% C2
0.45% C2 | Year 2019 2022 2023 2019 2019 2019 2019 2019 2019 2020 | IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
IV, Rando | 25 50
Favours [SAPB]
Mference
n, 95% CI |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Heterogeneity, Tau" = "
Test for overall effect 2
Eidemrdash 2019 [28]
Eidemrdash 2019 [28]
Eidemrdash 2019 [28]
Sagar 2022 [33]
Ahuja 2022 [31]
Nyima 2023 [30]
Bedewr 2023 [32]
Total (95% CI)
Heterogeneity, Tau" = 2
Study or Subgroup
Wang 2019 [28]
Eidemrdash 2
 | 31
0.64 (1.88 0.
0.00, Chi ^m = 2 = 0.70 (P
Mean
33
234
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
1011
10 | 1.1 4 0.76 4 0.076 4 0.076 4 0.001 4 dd

 | 50 3
10 0)
10 2
10 2
10
10 2
10 2
10
10 2
10
10 2
10
10
10
10
10
10
10
10
10
10 | an <u>\$</u>
3.3
64 0.0
38 0.00
S
Mean
3.3
3.64
2.25
0.0000
Mean
3.64
2.9281
Mean
3.64
3.64
2.905
2.9281
Mean
3.64
2.905
2.9281
Mean
3.64
2.2505
2.9281
Mean
3.64
2.2505
2.9281
Mean
3.64
3.64
2.2505
2.9281
Mean
3.64
3.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.64
2.255
0.555
0.555
0.555
0.555
0.555
0.555000
0.55500000000 | D Totate 1 55 14 1 57 14 9 9 9 11 14 9 9 9 9 11 14 9 11 14 9 11 19 9 10 13 3.93 0.089 0.001 0.715 0.001 0.715 0.001 1.1 1.93 3 3 3 3 3 3 3 0.745 0.765 0.765 0.745 0.786 0.786 0.745 0.786 0.786
 | 0 55.
0 44.
0 0.
0 100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
10 | ght
4%,
6%,
0%, -41
0%,
14,5%,
14,3%,
0,0%,
14,3%,
14,3%,
0,0%,
14,3%,
14,3%,
14,1%,
14,1%,
14,1%,
14,1%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
14,3%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
12,5%,
1 | IV, Random, 9 -0.19 [0.58,
0.00 [0.44,
9518] [573.87, -41 -0.10 [0.40, Std. Mean Differt
IV, Random,
0.00 [0.3] -0.10 [0.40, 91.8 [0.73, 28, 1 -0.6 [0.5,
-1.03 [1.6] -0.16 [0.40, -0.17 [0.40, -0.18 [0.0,
-0.06 [0.5,
-1.03 [1.6] -0.18 [0.1,
-0.16 [1.4] Std. Mean Differt
IV, Randor Std. Mean Differt
-0.06 [0.0, 0.00 [0,
-0.00 [0, 0.00 [0,
-0.00 [0, 0.00 [0,
-0.00 [0, 0.00 [0
 | 5% C1
0.20) :
0.44) :
0.44) :
0.44) :
0.44] :
0.44] :
0.44] :
0.44] :
0.44] :
0.44] :
0.44] :
0.35% C2
0.35% C2
0.35% C2
0.45% C2
0.44% C2
0.45% C2 | Year 2019 2022 2023 2019 2019 2019 2019 2019 2019 2020 | IV, Randon
-50 -25 0
Favours [ESPB]
Std. Mean I
IV, Randon
Favours [ESPB]
Std. Mean
IV, Randon
-4 -2 0
Favours [ESPB]
Std. Mean
IV, Randon | 25 50
Favours [SAPB]
Mference
n, 95% CI |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Héterogeneity, Tau" = 1
Test for overail effect 2
Study of Subgroup
Wang 2019 [28]
Eldemrdash 2019 [26]
Eldemrdash 2019 [26]
Heterogeneity, Tau" = 2
Test for overail effect 2
Study of Subgroup
Wang 2019 [28]
Eldemrdash 2 | 31
0.64 (1
1.88 0.
0.00, Chi [#]
Z = 0.70 (P
Mean
3 3
2.34
1.01
1.01
1.01
1.02
1.95
4.3590
94; Chi [#] =
0.24 (P
2.24 (P
2.24 (P)
2.24 (P) | 1.1 4 0.76 4 0.76 4 0.76 4 0.76 4 0.07 4 1 2 0.40, dl 2 0.87 11 2.66 0.001 0.881 0.001 0.081 0.001 0.081 0.001 1.1 1.946 5D 1.1 1.314 1 1.314 1 0.6227 0.001 0.033 0.627 0.001 1.1 1.59.12, = 0.77) ESPB 50 | 50 3
10 0.10 2
10 2
1 | an s
3.3
64 0.7
38 0.00
= 0.53); | SD Totate 1 50 1 56 41 91 91 44 99 91 303 0.089 0.001 0.55 0.766 0.765 0.711 1.4361 11,1383 3.93 0.5916 1.11 3.933 3.93 0.5916 1.3962 0.001 0.745 0.001 0.011) 001) 0.011 | 0 55.
0 44.
0 0 100.
Total
50 25
25 25
25 25
20 20
40
20
275
7%
Total
50 25
25 25
25 25
25 25
20 20
40 20
275
300
275
300
25
25
25
25
25
25
25
25
25
25 | ght
4%
6%
0% -41
14.5%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
12.6%
12.2%
12.2%
12.2%
12.2%
12.3%
12.3%
12.3%
12.3%
12.3% | IV, Random, 9 -0.19 [c.0.58] -0.19 [c.0.58] 0.00 [c.0.44, -0.10 [c.0.40, -0.01 [c.0.40, -0.01 [c.0.40, -0.01 [c.0.40, -0.04 [c.0.40, -0.05 [c.0.40, -0.05 [c.0.40, -0.06 [c.0.40, -0.06 [c.0.40, -0.06 [c.0.00 [c.0.40, -0.07 [c.0.40, -0.05 [c.1.40, -0.05 [c.1.40, <td>5% C1
0.201 :
0.201 :
0.41 :
6.491 :
9.5% C1
9.0.391 :
9.0.391 :
9.0.391 :
9.0.391 :
9.0.371 :
5.0.055 :
9.0.371 :
5.0.055 :
9.0.371 :
5.0.055 :
9.0.371 :
5.0.055 :
5.0.055 :
7.70.03 :
1.55 :
9.0.371 :
7.70.03 :
7.70</td> <td>2019
2022
2023
2023
2023
2029
2029
2020
2020</td> <td>IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
NV, Randor
Favours [ESPB]
Std. Mean
Std. Mean
Std. Mean
Std. Mean</td> <td>25 50
Favours [SAPB]
Afference
h, 95% CI</td> | 5% C1
0.201 :
0.201 :
0.41 :
6.491 :
9.5% C1
9.0.391 :
9.0.391 :
9.0.391 :
9.0.391 :
9.0.371 :
5.0.055 :
9.0.371 :
5.0.055 :
9.0.371 :
5.0.055 :
9.0.371 :
5.0.055 :
5.0.055 :
7.70.03 :
1.55 :
9.0.371 :
7.70.03 :
7.70 | 2019
2022
2023
2023
2023
2029
2029
2020
2020 | IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
NV, Randor
Favours [ESPB]
Std. Mean
Std. Mean
Std. Mean
Std. Mean | 25 50
Favours [SAPB]
Afference
h, 95% CI |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Heterogeneity: Tau" = "
Test for overall effect 2
Study or Subgroup
Wang 2019 [28]
Eldernrdash 2019 [28]
Eldernrdash 2019 [28]
Bedewy 2022 [31]
Nyima 2023 [30]
Bedewy 2022 [31]
Ahuja 2022 [31]
Nyima 2023 [30]
Bedewy 2023 [32]
Total (95% CI)
Heterogeneity: Tau" = 2
Study or Subgroup
Wang 2019 [28]
Eldernrdash 2019 [28]
Eldernrdash 2019 [28]
Eldernrdash 2019 [29]
Eldernrdash 2019 [20]
Eldernrdash 20
 | 31
0.64 (1.88 0.
0.00, Chi ^p H
= 0.70 (P
= 0.70 (P
Mean
3.3
2.34
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.01 | 1.1 4 0.76 4 0.76 4 0.76 4 0.076 4 0.076 5 0.1 1 1.1 2.65 0.001 2.65 0.001 2.65 0.002 0.003 0.681 0.001 1.946 50 0.001 1.1 3.14 1 0.7978 0.0571 0.7779 500

 | 50 3
50 3
50 3
50 0
50 2
50 5
50 5
52 5 | an s
33
33
464 0.0
53
80 00
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5 | D Totata 1 50 1 50 1 50 76 41 9 9 9 9 SD 11 3.93 1.1 3.93 0.001 1.44 0.089 0.001 1.4361 1.4361 3.4361 1.1 3.33 3.93 0.001 1.1 3.93 0.001 1.1 1.1 3.93 0.001 1.1 1.1 3.93 0.001 0.76 0.76 0.76 0.76 0.76 0.76 0.76 0.010 0.001 0.001 0.001 0.001 0.001 0.001 0.76 0.001 0.001
 | 0 55.
0 44.
0 0 100.
Total
Total
50
25
25
25
25
20
40
40
40
20
275
7%
Total
50
20
20
20
20
20
20
20
20
20
2 | ght
4%
6%
0% -41
14.5%
14.3%
0.0%
14.1%
14.3%
14.1%
14.3%
14.1%
14.3%
14.1%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
10.0%
10.0% | IV. Random, 9 -0.19 [-0.58, 0.00] (-0.44, 0.00] (-0.44, 0.00] (-0.44, 0.00] (-0.44, 0.00] (-0.40, 0.40] (-0.40,
 | 5% C1
0.201 :
0.201 :
0.41 :
0.441 :
0.441 :
0.449 :
0.441 :
0.449 :
0.441 :
0.441 :
0.441 :
0.441 :
0.441 :
0.455 :
0 | 2019
2022
2023
2023
2023
2029
2029
2029
202 | IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
NV, Randor
Favours [ESPB]
Std. Mean
Std. Mean
Std. Mean
Std. Mean | 25 50
Favours [SAPB]
htterence
n, 95% CI
 |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Héterogeneity, Tau" = 1
Test for overail effect 2
Study of Subgroup
Wang 2019 [28]
Eldemrdash 2019 [26]
Eldemrdash 2019 [26]
Bedewy 2023 [31]
Ahuja 2022 [31]
Ahuja 2022 [31]
Héterogeneity, Tau" = 2
Test for overail effect 2
Study of Subgroup
Wang 2019 [28]
Eldemrdash 2019 [26]
Eldemrdash 2019 [27]
Eldemrstava 2023 [32]
Ahuja 2022 [33]
Ahuja 2022 [34]
Eleedewy 2023 [32]
Nyima 2023 [30]
 | 31
0.64 (1
0.00, Chi [#]
= 0.70 (P
Mean
3.3
2.24
1.91
1.91
1.92
1.94
4.3590
94. Chi [#] =
0.24 (P
=
0.24 (P) =
0.24 (P
=
0.24 (P) =
0.24 (P) = | 1.1 1, 1
0.76 4
0.76 4
1.0.76 4
1.0.76 4
1.0.76 4
1.0.76 4
1.0.76 4
1.0.76 4
1.0.89 9
0.001 1
1.2.86 5
0.089 0.001 1
0.089 0.001 1
1.9.946 0.089 0.001 1
1.9.946 0.089 0.001 1
1.9.946 0.0001 1
1.9.946 0.0001 1
 | 50 3
10 0.10 2
10 2
1 | an s
3.3
64 0.7
38 0.00
= 0.53);
 | DI Total DI Total 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 3 1.1 3.93 0.001 1.4361 1.1 3.93 3.93 3.93 3.93 3.93 3.93 3.93 3.93 3.93 3.93 3.93 3.94 0.001 1.1 1.1 | 0 55.
0 44.
0 0 100.
Total
50 25
25 25
25 25
20 20
40
20
275
7%
Total
50 25
25 25
25 25
25 25
20 20
40 20
275
300
275
300
25
25
25
25
25
25
25
25
25
25
 | ght
4%
6%
0% -41
14.5%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.1%
14.1%
14.1%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5% | IV, Random, 29 -0.19[0.058, 0.00[0.44, 3518[573.87, 41] -0.10[0.040, 3518[573.87, 41] -0.10[0.040, 3518[573.87, 41] -0.10[0.040, 3518[573.87, 41] -0.10[0.040, 3518[573.87, 41] -0.10[0.040, 3518[573.87, 41] -0.10[0.040, 3518[50, 300] -0.00[0.05, 300] -0.010[0.05, 300] -0.04[0.05, 300] -0.04[0.05, 300] -0.04[0.05, 300] -0.05[0.11, 300] -0.06[0.05, 300] -0.06[0.05, 300] -0.06[0.05, 300] -0.06[0.05, 300] -0.06[0.05, 300] -0.06[0.05, 300] -0.06[0.05, 300] -0.06[0.05, 300] -0.06[0.05, 300] -0.06[0.05, 300] -0.06[0.05, 300] -0.06[0.05, 300] -0.06[0.05, 300] -0.06[0.00, 300] -0.06[0.00, 300] -0.06[0.00, 300] -0.06[0.00, 300] -0.06[0.00, 300] -0.06[0.00, 300] -0.06[0.00, 300] -0.06[0.00, 300] -0.06[0.00, 300] -0.06[0.00, 300]< | 5% C1
0.201 :
0.201 :
0.41 :
6.491 :
0.441 :
6.491 :
0.441 :
0.441 :
0.441 :
0.441 :
0.441 :
0.441 :
0.455 :
0.455 :
0.456 :
0.455 :
0 | Year Year 2019 2019 2019 2019 2019 2019 2019 2019 2019 2010 2020 2021 2022 2023 2021 2022 2023 2022 2023 2022 2023 1 2022 2023 1 2021 2022 1 2021 2022 2023 1 2022 2023 1 2021 2022 1 2022 2023 1 2024 1 2025 4
 | IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
NV, Randor
Favours [ESPB]
Std. Mean
Std. Mean
Std. Mean
Std. Mean | 25 50
Favours [SAPB]
Afference
h, 95% CI |
| Wang 2019 [28] Ahuja 2022 [31] Nyima 2023 [30] Total (95% CI) Heterogeneity, Tau" = 1 Test for overall effect 2 Study or Subgroup Wang 2019 [28] Elderndash 2019 [26] Elderndash 2019 [26] Elderndash 2019 [26] Bedew 2023 [21] Nyina 2021 [24] Heterogeneity, Tau" = 2 Total (95% CI) Heterogeneity, Tau" = 2 Test for overall effect Z Study or Subgroup Wang 2019 [28] Eldernrdash 2019 [28] Heterogeneity, Tau" = 1 Test for overall effect 2 Wang 2019 [28] Test for overall effect 2 Wang 2019 [28] Eldernrdash 2019 [28]
 | 31
0.64 (
0.00, Chi [#] =
2 = 0.70
(P
Mean
3.3
2.34
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01 | 1.1 1, 1
0.76 4
0.76 4
0.76 4
1.0.76 4
1.0.76 4
1.0.76 4
1.0.76 4
1.0.76 4
1.0.89 9
0.001 1
1.2.85 8
0.089 0.001 1
0.089 0.001 1
1.1.946 0.885 0.076 0.089 0.001 1
1.9946 0.001 1
1.99
 | 50 3 50 3 60 1 7 1 | an s
an s
an s
an s
an s
an s
an s
an s
 | D1 Total 1 50 76 41 1 51 76 41 91 91 92 92 1.1 3.93 3.93 3.93 3.91 1.1 1.4361 0.061 1.1 1.4361 3.93 3.0516 0.001 1.1 1.3962 0.745 0.745 0.745 0.741 1.3962 0.011); I*= SAPB SD 1.1 3.33 3 | 0 55.0 0 44.0 0 0.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 25 25 20 40 20 20 20 20 20 20 25 30 25 30 255 30 < | ght
4%
6%
0%
-41
14.5%
14.3%
14.3%
0.0%
14.1%
0.0%
14.1%
14.3%
14.3%
14.3%
14.3%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12% | IV, Random, 29 -0.19[0.058, 0.00[0.44, 3518[573.87, 41] -0.10[0.040, 3518[573.87, 41] -0.10[0.040, 3518[573.87, 41] -0.10[0.040, 3518[573.87, 41] -0.10[0.040, 3518[573.87, 41] -0.10[0.040, 3518[573.87, 41] -0.10[0.040, 3518[50, 300] -0.06[0.05, 10, 301, 10] -0.06[0.05, -1, 0.31, 10] -0.06[0.5, -1, 0.31, 10] -0.06[0.5, -1, 0.31, 10] -0.06[0.5, -1, 0.31, 10] -0.06[0.5, -1, 0.31, 10] -0.16[0.1, 0.00[0.5, -0.00[0.5, 0.0 | 5% C1
0.201 :
0.201 :
0.441 :
6.491 :
0.441 :
0.441 :
9.039, 0.39
94.0181 :
9.039 :
44.0181 :
9.039 :
44.0181 :
9.039 :
1.055 :
0.55 :
0.451 :
9.037 :
0.39 :
0.30 :
0.39 :
0.39 :
0.31 | Year Year 2019 2019 2019 2019 2019 2019 2019 2019 2019 2010 2020 2021 2022 2023 2021 2022 2023 2022 2023 2022 2023 1 2022 2023 1 2021 1 2021 1 2022 2023 1 2021 1 2022 1 2023 1 2021 1 2023 1 2024 1 2025 1 2021 1 2021
 | IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
NV, Randor
Favours [ESPB]
Std. Mean
Std. Mean
Std. Mean
Std. Mean | 25 50
Favours [SAPB]
Afference
h, 95% CI |
| Wang 2019 [28] Ahuja 2022 [31] Nyima 2023 [30] Total (95% CI) Heterogeneity: Tau" = 1 Test for overall effect 2 Study or Subgroup Wang 2019 [28] Elderndrash 2019 [28] Elderndrash 2019 [28] Elderndrash 2019 [28] Bedewy 2022 [21] Nyima 2023 [20] Bedewy 2023 [21] Total (95% CI) Heterogeneity: Tau" = 2 Study or Subgroup Wang 2019 [28] Elderndrash 2019 [28] <t< td=""><td>31
0.64 (1.88 0.
0.00, Chi^p H
= 0.70 (P
= 0.70 (P
Mean
3.3
2.34
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.01</td><td>1.11 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1</td><td>50 3
50 3
50 3
50 0
50 2
50 3
50 30 3
50 30 30 30
50 30 30 30
50 30 30
50 30 30
50 30 30
50 30 30
50 30 30
50 30 30 30
50 30 30 30
50 30 30 30
50 30 30 30 30
50 30 30 30 30 30 30 30 30 30 30 30 30 30</td><td>an s
an s
an s
an s
an s
an s
an s
an s</td><td>DD Totat 75
DT T</td><td>0 55.0 0 44.0 0 0.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 200 200</td><td>ght
4%
6%
0% -4(
14.5%
14.3%
14.5%
0.0%
14.1%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
12.5%
12.5%
12.5%
10.0%
Weight
12.2%
12.5%
12.5%
12.5%
12.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15</td><td>IV, Random, 9 -0.19 [c.58,
0.00 [c.44,
95.18 [c.57.387, 41] -0.10 [c.0.40,
95.18 [c.57.387, 41] -0.10 [c.0.40,
95.18 [c.57.387, 41] -0.10 [c.0.40,
0.00 [c.0.30, 00] 904.29 [703.28, 1] -0.06 [c.0.30, 00] 904.29 [703.28, 1] -0.06 [c.0.30, 10] -0.06 [c.0.30, 10] -0.16 [-1.4 Std. Mean Differ ty, Random -0.16 [-1.4 Std. Mean Differ ty, Random -0.08 [c.5, 26] -0.18 [c.0.35 [c.0.35] -0.35 [c.6] -0.35 [c.6] Std. Mean Differ ty, Random 0.00 [c.0.00 [c.0.35 [c.6] -0.35 [c.6] -0.35 [c.6] -0.35 [c.6] -0.35 [c.6] std. Mean Differ ty, Random Std. Mean Differ ty, Random -455 [c.527 [c.6] -455 [c.527 [c.6] std. Mean Differ ty, Random 6 0.02 [c.6] 6 0.02 [c.6] 6<td>5% C1
0.201 :
0.201 :
0.441 :
6.491 :
95% C1
95% C1</td><td>2019
2022
2022
2023
2023
2029
2019
2019
2020
2021
2020
2021
2022
2023
2023
2023</td><td>IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
NV, Randor
Favours [ESPB]
Std. Mean
Std. Mean
Std. Mean
Std. Mean</td><td>25 50
Favours [SAPB]
Afference
h, 95% CI</td></td></t<> | 31
0.64 (1.88 0.
0.00, Chi ^p H
= 0.70 (P
= 0.70 (P
Mean
3.3
2.34
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.011
1.01 | 1.11 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 | 50 3
50 3
50 3
50 0
50 2
50 3
50 30 3
50 30 30 30
50 30 30 30
50 30 30
50 30 30
50 30 30
50 30 30
50 30 30
50 30 30 30
50 30 30 30
50 30 30 30
50 30 30 30 30
50 30 30 30 30 30 30 30 30 30 30 30 30 30 | an s
an s
an s
an s
an s
an s
an s
an s | DD Totat 75
DT T | 0 55.0 0 44.0 0 0.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 200 200 | ght
4%
6%
0% -4(
14.5%
14.3%
14.5%
0.0%
14.1%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
12.5%
12.5%
12.5%
10.0%
Weight
12.2%
12.5%
12.5%
12.5%
12.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15.5%
15 | IV, Random, 9 -0.19 [c.58,
0.00 [c.44,
95.18 [c.57.387, 41] -0.10 [c.0.40,
95.18 [c.57.387, 41] -0.10 [c.0.40,
95.18 [c.57.387, 41] -0.10 [c.0.40,
0.00 [c.0.30, 00] 904.29 [703.28, 1] -0.06 [c.0.30, 00] 904.29 [703.28, 1] -0.06 [c.0.30, 10] -0.06 [c.0.30, 10] -0.16 [-1.4 Std. Mean Differ ty, Random -0.16 [-1.4 Std. Mean Differ ty, Random -0.08 [c.5, 26] -0.18 [c.0.35 [c.0.35] -0.35 [c.6] -0.35 [c.6] Std. Mean Differ ty, Random 0.00 [c.0.00 [c.0.35 [c.6] -0.35 [c.6] -0.35 [c.6] -0.35 [c.6] -0.35 [c.6] std. Mean Differ ty, Random Std. Mean Differ ty, Random -455 [c.527 [c.6] -455 [c.527 [c.6] std. Mean Differ ty, Random 6 0.02 [c.6] 6 0.02 [c.6] 6 <td>5% C1
0.201 :
0.201 :
0.441 :
6.491 :
95% C1
95% C1</td> <td>2019
2022
2022
2023
2023
2029
2019
2019
2020
2021
2020
2021
2022
2023
2023
2023</td> <td>IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
NV, Randor
Favours [ESPB]
Std. Mean
Std. Mean
Std. Mean
Std. Mean</td> <td>25 50
Favours [SAPB]
Afference
h, 95% CI</td> | 5% C1
0.201 :
0.201 :
0.441 :
6.491 :
95% C1
95% C1 | 2019
2022
2022
2023
2023
2029
2019
2019
2020
2021
2020
2021
2022
2023
2023
2023 | IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
NV, Randor
Favours [ESPB]
Std. Mean
Std. Mean
Std. Mean
Std. Mean | 25 50
Favours [SAPB]
Afference
h, 95% CI |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Heterogeneity, Tau* =
Test for overall effect 2
Study or Subgroup
Elderndash 2019 [26]
Elderndash 2019 [26]
Elderndash 2019 [27]
Hohya 2021 [21]
Nyima 2023 [31]
Nyima 2023 [32]
Heterogeneity, Tau* = 2
Test for overall effect 2
Study or Subgroup
Wang 2019 [28]
Elderndash 2019 [28]
El
 | 31
0.64 (
0.00, Chi [#] =
2 = 0.70 (P
Mean
3.3
2.34
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01
1.01 | 1.1 1, 1
0.76 4
0.76 4
0.76 4
1.0,76 4
1.0,76 4
1.0,80 4
1.0,90 4
1.
 | 50 3 50 3 60 1 7 1 7 1
7 1 | an s
an s
an s
an s
an s
an s
an s
an s | DT Total and 101 41 11 57 11 16 76 41 99 99 91 91 101 41 11 51 50 76 11 31 30 0.001 0.716 0.001 0.715 0.001 11,1333 33 0.391 0.001 0.011); P = 50 SAPB 50 0.001 1.1 333 3 0.5916 1.1 3.933 3 0.5916 1.1 3.933 3
 | 0 55.0 0 44.0 0 0.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 100.0 0 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 25 25 20 40 20 20 20 20 20 20 25 30 25 30 255 30 < | ght
4%
6%
0% -41
14.5%
14.3%
14.3%
0.0%
14.1%
0.0%
14.1%
14.3%
14.3%
14.3%
14.3%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12.2%
12% | IV, Random, 9 -0.19[0.058,
0.00[0.44,
95.18[-57.3.87, -41] -0.10[0.40,
95.18]-57.3.87, -41 -0.10[0.40,
95.18]-57.3.87, -41 -0.10[0.40,
95.18]-57.3.87, -41 -0.10[0.40,
964.29]703, 28, 1 -0.06[0.5,
-10.36]+0.9 904.29[703, 28, 1 -0.06[0.5,
-10.36]+0.9 -0.06[0.5,
-10.36]+0.9 -0.16[1.4 Std. Mean Differ V, Random -0.16[0.1 -0.16[1.4 Std. Mean Differ V, Randor -0.06[0.2, 0.00] -0.07[0.4] -0.18[0.1 -0.08[0.2] -0.08[0.1] -0.08[0.1] -0.18[0.1] -0.05[5] -0.05[5] -0.05[6] -0.05[6] -0.05[6] -0.05[6] -0.05[6] -0.05[6] -0.05[6] -0.05[6] -0.13[1] Std. Mean Differ V, Randor 0.00[0.6] -0.07[0.6] -0.08[0.6]
 | 5% C1
0.201
0.201
6.491
6.491
0.441
6.491
0.441
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
4.018
9.039
1.055,055
1.055,055
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.0000
1.00000
1.00000
1.00000
1.00000
1.00000
1.00000
1.00000
1.0000000
1.00000000 | 2019 2019 2022 2023 2023 2019 2019 2019 2020 2020 2021 2020 2021 2020 2021 2022 2022 2023 2022 2023 2022 2023 2022 2023 2021 2022 2022 2023 1 2021 1 2021 1 2021 1 2022 1 2022 1 2024 9 2019 1 2021 1 2024 9 2019 1 2021 1 2021 1 2021 1 2021 1 2021 1 2021 1 2021 1 2021 1 2021 1 | IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
NV, Randor
Favours [ESPB]
Std. Mean
Std. Mean
Std. Mean
Std. Mean | 25 50
Favours [SAPB]
Afference
h, 95% CI |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Heterogeneity: Tau" = '
Test for overall effect 2
Elsabeery 2020 [27]
Shrivastava 2021 [24]
Eldernrdash 2019 [26]
Eldernrdash 2019 [26]
Bedewy 2022 [31]
Nyima 2023 [30]
Bedewy 2022 [31]
Ahuja 2022 [31]
Nyima 2023 [32]
Total (95% CI)
Heterogeneity: Tau" = 2
Study or Subgroup
Wang 2019 [28]
Eldernrdash 2019 [26]
Eldernrdash 2019 [26]
Eldernrdash 2019 [30]
Heterogeneity: Tau" = 1
Total (95% CI)
Heterogeneity: Tau" = 1
Total (95% CI)
Heterogeneity: Tau" = 1
Total (95% CI)
Heterogeneity: Tau" = 1
Test for overall effect 2
Study or Subgroup
Wang 2019 [28]
Eldernrdash 2019 [26]
Eldernrdash 2019 [26]
Eldernrdash 2019 [27]
Eldernrdash 2019 [28]
Eldernrdash 2019 [29]
Eldernrdash 2019 [29]
Eldernrdash 2019 [29]
Eldernrdash 2019 [29]
 | 31
0.64 (1
0.00, Chi [#] =
2 = 0.70 (P
Mean
3.3
2.24
1.01
1.01
9.4 (Chi [#] =
0.24 (P =
0 | 1.1 1, 1
0.76 4
0.76 4
0.76 4
1.0.76 4
1.0.76 4
1.0.76 4
1.0.76 4
1.0.89 9
0.001 1
1.2.65 4
0.089 0
0.099 0.001 1
1.2.946 0.089 0.001 1
1.1.946 0.089 0.001 1
1.1.946 0.089 0.001 1
1.1.946 0.001 0.077 0.0778 0.001 1
1.5.912 0.0777 0.001 1
1.5.912 0.001 0
1.5.912 0.001 0
1.5.912 0.001 0
1.5.912 0.001 0
1.5.912 0.001 0
1.5.912 0.001 0
1.5.912 0.001 0
0.777 0
0.001 0
0.777 0
0.777 0
0.001 0
0.777 0
0.777 0
0.001 0
0.777 0
0.001 0
0.777 0
0.777 0
0.001 0
0.777 0
0.001 0
0.777 0
0.0

 | 50 3 50 3 60 1 7 1 | an <u>s</u>
an <u>a</u>
an <u>a</u>
a <u>a</u>
an <u>a</u>
a
<u>a</u>
a
<u>a</u>
a
<u>a</u>
a
<u>a</u>
a
<u>a</u>
a
<u>a</u>
a
a | DT Total and 101 41 11 51 765 41 91 91 <td>0 55. 0 40. 0 0 0 100. 0 100. 100 100. 100 100. 100 100. 100 100. 100 100. 100 100. 100 20. 200</td> <td>ght
4%
6%
0% -41
14.5%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
12.5%
12.5%
12.5%
12.5%
12.5%
10.0%</td> <td>IV, Random, 9 -0.19[0.58,
0.00[0.44,
95.18[573.87, 41] -0.10[0.40,
95.18[573.87, 41] -0.10[0.40,
95.18]573.87, 41] -0.10[0.40,
95.18]573.87, 41] -0.10[0.40,
964.29]703.28, 1 -0.06[0.5,
-0.08[0.5] -0.13[1.6] -0.14[0.6] -0.16[1.6] -0.18[1.0] -0.16[1.6] -0.18[1.0] -0.16[1.6] -0.18[1.0] -0.18[1.0] -0.16[1.4] Std. Mean Differ V, Randor -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.5556[1.27].86, -0.13[1.1] Std. Mean Differ V, Randor 0.00[0.0] -0.05[0.0] -0.556[1.1] -0.556[</td> <td>5% C1
0.201 ;
0.201 ;
0.441 ;
6.499 ;</td> <td>Year 2019 2019 2019 2019 2019 2019 2019 2019 2012 2020 2021 2022 2023 4</td> <td>IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
NV, Randor
Favours [ESPB]
Std. Mean
Std. Mean
Std. Mean
Std. Mean</td> <td>25 50
Favours [SAPB]
Afference
h, 95% CI</td> | 0 55. 0 40. 0 0 0 100. 0 100. 100 100. 100 100. 100 100. 100 100. 100 100. 100 100. 100 20. 200 | ght
4%
6%
0% -41
14.5%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
12.5%
12.5%
12.5%
12.5%
12.5%
10.0%
 | IV, Random, 9 -0.19[0.58,
0.00[0.44,
95.18[573.87, 41] -0.10[0.40,
95.18[573.87, 41] -0.10[0.40,
95.18]573.87, 41] -0.10[0.40,
95.18]573.87, 41] -0.10[0.40,
964.29]703.28, 1 -0.06[0.5,
-0.08[0.5] -0.13[1.6] -0.14[0.6] -0.16[1.6] -0.18[1.0] -0.16[1.6] -0.18[1.0] -0.16[1.6] -0.18[1.0] -0.18[1.0] -0.16[1.4] Std. Mean Differ V, Randor -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.18[1.0] -0.5556[1.27].86, -0.13[1.1] Std. Mean Differ V, Randor 0.00[0.0] -0.05[0.0] -0.556[1.1] -0.556[| 5% C1
0.201 ;
0.201 ;
0.441 ;
6.499 ; | Year 2019 2019 2019 2019 2019 2019 2019 2019 2012 2020 2021 2022
2023 4 | IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
NV, Randor
Favours [ESPB]
Std. Mean
Std. Mean
Std. Mean
Std. Mean | 25 50
Favours [SAPB]
Afference
h, 95% CI |
| Wang 2019 [28] Ahuja 2022 [31] Nyima 2023 [30] Total (95% CI) Heterogeneity: Tau" = 1 Test for overall effect 2 Study of Subgroup Wang 2019 [28] Elderndish 2019 [28] Elderndish 2019 [28] Elderndish 2019 [28] Elderndish 2019 [28] Bedewy 2022 [21] Nyma 2023 [20] Bedewy 2023 [21] Total (95% CI) Heterogeneity: Tau" = 2 Study of Subgroup Wang 2019 [28] Elderndish 2019 [28] Eldernidish 2019 [28 | 31
0.64 (1.88 0.
0.00, Chi ^p H
= 0.70 (P
= 0.70 (P
1.148 0.
1.148 0.
1.148 0.
1.148 0.
1.148 0.
1.148 0.
1.141 1.
1.141 1. | 1.11 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 | 50 3
50 3
50 0 0
50 0 2
50 0
50 0
50 2
50 2
5 | an <u>s</u>
an <u>a</u>
an | DD Totat 75
DD T | 0 55.
50 44.
0 44.
0 44.
0 0.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
1 | ght
4%
6%
0% -41
14.5%
14.3%
14.3%
0.0%
14.3%
14.3%
14.3%
14.3%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5% | IV, Random, 9 -0.19 [c.56, 0.00 [c.0.44, 95.18 [c.57.3.87, 41] -0.10 [c.0.40, 95.18 [c.57.3.87, 41] -0.00 [c.0.5 [c.57.48 [c.57. | 5% C1
0.201
0.201
6.49
5.0441
5.0441
5.0441
5.0441
5.0441
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.0451
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055
5.055 | Year 2019 2019 2019 2019 2019 2019 2019 2019 2019 2019 2019 2012 2021 2022 2023 2022 2023 2022 2023 2021 2022 2023 1 2021 2022 2023 1 2021 2023 9 2024 1 2025 2021 2023 9 2024 9 2025 9 2020 9 2021 9 2022 1022 11 2022 2023 12 | IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
NV, Randor
Favours [ESPB]
Std. Mean
Std. Mean
Std. Mean
Std. Mean | 25 50
Favours [SAPB]
Afference
h, 95% CI |
| Wang 2019 [28]
Ahuja 2022 [31]
Nyima 2023 [30]
Total (95% CI)
Héterogeneity: Tau* = '
Test for overall effect 2
Eisabeery 2020 [27]
Shrivastava 2021 [24]
Eiderndash 2019 [26]
Eiderndash 2019 [26]
Bedewy 2022 [31]
Nyima 2023 [30]
Heterogeneity: Tau* = 2
Test for overall effect 2
Study or Subgroup
Wang 2019 [26]
Eiderndash 2019 [26]
Eiderndash 2019 [26]
Eiderndash 2019 [27]
Jania 2021 [29]
Shrivastava 2021 [31]
Nyima 2023 [30]
Nyima 2023 [30]
Heterogeneity: Tau* = 2
Test for overall effect 2
Study or Subgroup
Heterogeneity: Tau* = 1
Test for overall effect 2
Study or Subgroup
Heterogeneity: Tau* = 1
Test for overall effect 2
Study or Subgroup
Wang 2019 [26]
Eiderndash 2019 [| 31
0.64 (1
0.00, Chi [#] =
2 = 0.70 (P
Mean
3.3
2.24
1.01
1.01
9.4 (Chi [#] =
0.24 (P =
0 | 1.11 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 | 50 3 50 3 60 2 60 7 70 7 <tr td=""></tr> | an <u>s</u>
an <u>a</u>
an <u>a</u> an <u>a</u> an <u>a</u>
an <u>a</u>
an <u>a</u>
an <u>a</u> an <u>a</u> an <u>a</u>
an <u>a</u>
an <u>a</u>
an <u>a</u>
an <u>a</u> an <u>a</u>
an <u>a</u>
a <u>a</u>
an <u>a</u>
a
<u>a</u>
a
<u>a</u>
a
<u>a</u>
a
<u>a</u>
a
<u>a</u>
a
<u>a</u>
a
a | DD Totat 75
DD T | 0 55.
0 44.
0 44.
0 44.
0 0.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
10 | ght
4%
6%
0% -41
14.5%
14.3%
14.3%
14.3%
0.0%
14.14.3%
14.3%
0.0%
14.14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%
14.3%14.3%
14.3%
14.3%
14.3%14.3%
14.3%14.3%
14.3%
14.3%14.3%
14.3%14.3%
14.3%14.3%
14.3%
14.3%14.3%
14.3%14.3%
14.3%
14.3%14.3%
14.3%14.3%
14.3%14.3%
14.3%14.3%
14.3%14.3%14.3%
14.3%14.3%
14.3%14.3%14.3%
14.3%14.3%
14.3%14.3%14.3%
14.3%14.3%14.3%
14.3%14.3%14.3%
14.3%14.3%14.3%
14.3%14.3%14.3%
14.3%14.3%14.3%
14.3%14.3%14.3%
14.3%14.3%14.3%
14.3%14.3%
14.3%14.3%14.3%
14.3%14.3%
14.3%14.3%14.3%
14.3%14.3%14.3%14.3%14.3%14.3%14.3%14.3%14.3%14.3%14.3%14.3%14. | IV, Random, 9 -0.19 [c.56,
0.00 [c.0.44,
95.18 [c.57.387, 41] -0.10 [c.0.40,
95.18 [c.57.387, 41] -0.10 [c.0.40,
95.18 [c.57.387, 41] -0.10 [c.0.40,
0.00 [c.0.30,
0.00 [c.0.30,
984.29 [763.28, 1] -0.00 [c.0.30,
984.29 [763.28, 1] -0.06 [c.0.30,
0.01 [c.0.40,
0.01 [c.0.40,
0.01 [c.0.40,
0.01 [c.0.40,
0.00 [c. | 5% C1
0.201 :
0.201 :
0.441 :
6.491 :
95% C1
95% C1 | 2019
2022
2022
2023
2023
2029
2029
2029
202 | IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
NV, Randor
Favours [ESPB]
Std. Mean
Std. Mean
Std. Mean
Std. Mean | 25 50
Favours [SAPB]
Afference
h, 95% CI |
|
 |
 |
 | |
 | | | | | | | | | | | | | |
 | | |
 | | |
| Wang 2019 [28] Ahuja 2022 [31] Nyima 2023 [30] Total (95% CI) Heterogeneity: Tau" = 1 Test for overall effect 2 Study of Subgroup Wang 2019 [28] Elderndish 2019 [28] Elderndish 2019 [28] Elderndish 2019 [28] Elderndish 2019 [28] Bedewy 2022 [21] Nyma 2023 [20] Bedewy 2023 [21] Total (99% CI) Heterogeneity: Tau" = 2 Study of Subgroup Wang 2019 [28] Elderndish 2019 [28] Eldernidish 2019 [28 | 3 1
0.64 (
0.00, Chi [#]
= 0.70 (P
Mean
3 3
2 24
1 01
1 01
1 01
94; Chi [#] =
0 24 (P
=
0 24 (P
=
0 24 (P
=
0 24 (P
=
0 24 (P
=
0 24 (P
=
0 20 (P
-
0 2
-
0 2
-
-
0 2
-
-
-
-
-
-
-
-
-
-
-
-
- | 1.1 1 1 0.76 4 0.76 4 0.76 4 0.76 4 0.76 4 0.76 4 0.76 4 0.76 4 0.76 4 0.76 4 0.76 4 0.76 4 0.76 4 0.76 6 0.76 6 0.76 6 0.76 6 0.76 6 0.76 6 0.76 6 0.77 6 0.76 7 0.77 7 0.00 1 1.946 5 0.77 7 0.00 1 1.946 5 0.77 7 0.00 1 1.946 5 0.77 7 0.00 1 1.946 5 0.77 7 0.00 1 1.946 5 0.77 7 1.946 5 0 0.77 7 1.946 5 0 0.77 7 1.946 5 0 0.77 7 1.946 5 0 0.77 7 1.946 5 0 0.77 7 1.946 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 50 3
50 3
50 3
50 3
50 2
50 2
50 5
50 2
525 5
525 5
52 | an s
an 64 0.0
33
64 0.0
33 0.00
s
s
mean
3.3
3.64
1.011
1.28
2.25
0.64
2.2805
2.29281
< 0.0000
//> | DD Totata
DD Totata
SD Totata | 0 55.
0 44.
0 44.
0 44.
0 0.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
100.
10 | ght
4%
6%
0% -41
14.5%
14.3%
14.3%
0.0%
14.3%
14.3%
14.3%
14.3%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5%
12.5% | IV, Random, 9 -0.19 [c.56, 0.00 [c.0.44, 0.00 [c.0.44, 0.00 [c.0.44, 0.00 [c.0.44, 0.00 [c.0.46, 0.00 [c.0.45, | 5% C1
0.201 :
0.201 :
0.441 :
6.491 :
95% C1
95% C1 | 2019
2022
2022
2023
2023
2029
2029
2029
202 | IV, Randon
Favours [ESPB]
Std. Mean
Favours [ESPB]
Std. Mean
NV, Randor
Favours [ESPB]
Std. Mean
Std. Mean
Std. Mean
Std. Mean | 25 50
Favours [SAPB]
Afference
h, 95% CI |

Fig. 5 (See legend on previous page.)





Fig. 6 a Postoperative pain scores (dynamic) at 0 h. b Postoperative pain scores (dynamic) at 8 h. c Postoperative pain scores (dynamic) at 8 h (forest plot for sensitivity analysis). d Postoperative pain scores (dynamic) at 12 h. e Postoperative pain scores (dynamic) at 12 h (forest plot for sensitivity analysis). f Postoperative pain scores (dynamic) at 24 h. g Postoperative pain scores (dynamic) at 24 h (forest plot for sensitivity analysis). f Postoperative pain scores (dynamic) at 24 h. g Postoperative pain scores (dynamic) at 24 h (forest plot for sensitivity analysis). SMD standard mean difference, CI confidence interval, IV inverse variance, SD standard deviation, ESPB erector spinae plane block, SAPB serratus anterior plane block

	ESP	B	SAPB		Risk Ratio			Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% Cl		
Elsabeeny 2020 [27]	5	25	6	25	5.4%	0.83 [0.29, 2.38]	2020	· · ·		
Shrivastava 2021 [34]	20	25	15	25	42.2%	1.33 [0.92, 1.94]	2021			
Ahuja 2022 [31]	29	40	22	40	51.7%	1.32 [0.94, 1.85]	2022			
Nyima 2023 [30]	0	40	2	40	0.7%	0.20 [0.01, 4.04]	2023	•		
Total (95% CI)		130		130	100.0%	1.28 [1.00, 1.63]				
Total events	54		45							
Heterogeneity: Tau ² = 0.	00; Chi ² =	= 2.44,	df = 3 (P :	= 0.49)	² = 0%			0.7 0.85 1 1.2 1.5		
Test for overall effect: Z	= 1.96 (P	= 0.05)						0.7 0.85 1 1.2 1.5 Favours [ESPB] Fsvours [SAPB]		

Fig. 7 Forest plot for number of patients requested analgesia in first 24 h postoperatively. RR relative risk, CI confidence interval, M–H Mantel– Haenszel, SD standard deviation, ESPB erector spinae plane block, SAPB serratus anterior plane block



Total (95% CI) 70 70 100.0% Heterogeneity: Tau² = 0.00; Chi² = 1.50, df = 2 (P = 0.47); l² = 0% Test for overall effect: Z = 8.47 (P < 0.00001)

4.11

40

6.46

2.95

40

9.57

b

Nyima 2023 [30]

Fig. 8 a Forest plot for time to request the first dose of postoperative analgesia. b Forest plot for time to request the first dose of postoperative analgesia (sensitivity analysis). MD mean difference, CI confidence interval, IV inverse variance, SD standard deviation, ESPB erector spinae plane block, SAPB serratus anterior plane block

0.0%

3.11 [1.54, 4.68]

1.49 [1.15, 1.83]

2023

	E	ESPB			SAPB			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Jiang 2021 (29)	8	1.55	30	8	1.55	30	17.2%	0.00 [-0.78, 0.78]	2021	
Ahuja 2022 [31]	5.7	0.76	40	6.1	0.87	40	82.8%	-0.40 [-0.76, -0.04]	2022	
Total (95% CI)			70			70	100.0%	-0.33 [-0.66, -0.01]		•
Heterogeneity: Tau ² = Test for overall effect:				= 1 (P =	0.36);	I² = 0%				-2 -1 0 1 2 Favours [ESPB] Favours [SAPB]


Fig. 9 Forest plot for postoperative satisfaction score. MD mean difference, CI confidence interval, IV inverse variance, SD standard deviation, ESPB erector spinae plane block, SAPB serratus anterior plane block

Postoperative nausea and vomiting

Three articles [32, 33, 35] evaluated nausea and vomiting incidence. Both groups of patients reported similar incidences of nausea and vomiting (RR = 1.10, [0.66, 1.84], p = 0.72, $I^2 = 0\%$ (Fig. 10a) and RR = 1.27, [0.47, 3.44], p = 0.64, $I^2 = 0\%$) (Fig. 10b), respectively. No instudy heterogeneity was reported in either. An asymmetrical appearance on visual inspection of the funnel

-2

Favours [ESPB] Favours [SAPB]






Fig. 10 a Forest plot for nausea. b Forest plot for vomiting (adverse effects of the blocks). RR relative risk, CI confidence interval, M–H Mantel– Haenszel, SD standard deviation, ESPB erector spinae plane block, SAPB serratus anterior plane block

plots of both outcomes was seen (online supplemental appendix C).

Discussion

This systematic review and meta-analysis aimed to compare the analgesic efficacy and safety profiles of the ESPB and SAPB in the context of breast surgery. While the primary analysis showed no significant difference in postoperative pain scores, ESPB demonstrated a statistically significant reduction in morphine consumption compared to SAPB. However, this difference did not reach clinical significance based on our predefined criteria [33]. Secondary outcomes also indicated no notable differences in pain scores and patient satisfaction between the two techniques.

The findings of this study hold implications for the management of postoperative pain in patients undergoing breast surgery since this is the first review conducted to compare the analgesic modalities in that population. This insight is crucial for clinicians in making informed decisions regarding pain management strategies, especially considering the increasing preference for minimally invasive and ultrasound-guided techniques in regional anesthesia. Future trials should assess analgesic efficacy over longer postoperative duration, i.e., 24 to 72 h. Additionally, among the included RCTs, only one study compared postoperative rehabilitation indicators among both groups [37]. Future studies with relatively large sample sizes comparing the efficacy in terms of postoperative rehabilitation indicators and the safety of blocks in terms of block-related complications and their effect on overall patients' quality of life can also provide valuable evidence as to which block is superior to the other.

From an anatomical perspective, the ESPB and SAPB target different nerve distributions, which may explain their analgesic effects. The ESPB, a paraspinal fascial plane block, targets the dorsal and ventral rami of thoracic spinal nerves, providing a comprehensive sensory block-ade that can extend to abdominal visceral analgesia. This broad range of analgesia may contribute to its efficacy in reducing postoperative morphine consumption. On the other hand, the SAPB selectively targets the lateral cutaneous branches of thoracic intercostal nerves, resulting in paresthesia across T2 to T9 dermatomes. This selective blockade is beneficial for managing pain localized to the surgical site, a common feature in breast surgery.

According to the Regional Anaesthesia UK, ESPB is one of the seven "Plan A" blocks for commonly encountered surgeries and acute pain. This is because ESPB can be administered at all the levels of the spine and provides analgesia to most body regions [39]. Moreover, the versatile use of ESPB especially in individuals on antithrombotic medications is due to its "superficial block" nature as opposed to deeper paravertebral or epidural blocks that may lead to bleeding due to the block administration [40]. The American Society of Regional Anesthesia has classified ESPB as a "low risk" for bleeding complications [41]. Given postoperative bleeding is a common and serious complication in breast surgery, the ESPB can be preferred [42]. The safety profile of ESPB is further exemplified with a lower incidence of pneumothorax when compared to other nerve blocks such as the paravertebral block [43]. Additionally, according to Luff et al. [44], trainee anesthetists have the most confidence in administering ESPB over other "Plan A" blocks and rates of block failures are less than 1/10th when performed by inexperienced anesthetists [45].

The SAPB can be injected superficially between the latissimus dorsi and serratus anterior muscle or deeply between the serratus anterior and intercostal muscle. With superficial SAPB providing more extensive effect and a greater safety profile than deep SAPB, there is discordance among the evidence since according to Moon et al. [46], the efficacy is similar while according to Piracha et al. [47], deep SAPB is more effective for postmastectomy pain control. More evidence can help decided the SAPB injection strategy. According to a meta-analysis by Meng et al. [48], SAPB can also reduce the incidence of chronic postsurgical pain after breast surgery highlighting its long-term use.

Strengths and limitations

This systematic review, a comparison of ESPB and SAPB for postoperative analgesia following breast cancer surgery, is one in its own way and has not yet been the subject of a meta-analysis. It has several strengths, including adherence to reporting standards mentioned in PRISMA guidelines, a robust literature search strategy that included both the English and non-English RCTs, and a thorough assessment of the methodological quality and risk of bias of included studies. The inclusion of nine RCTs from diverse geographic regions enhances the generalizability of the findings. Moreover, the results were interpreted by taking into account MCID to avoid overestimating the statistically significant differences. Furthermore, the use of sensitivity and subgroup analyses helped address heterogeneity and provide a more precise understanding of the results.

However, the study also has limitations. The high degree of heterogeneity observed in some analyses suggests variability in study design, patient populations, and intervention protocols. Although sensitivity analyses partially addressed this issue, some residual heterogeneity remained unexplained that may have arisen from different local anesthetic agents and adjunct medications across studies. Lastly, while the overall strength of evidence was moderate to low for most outcomes, the limited number of studies and small sample sizes in some analyses hindered our ability to estimate some of the rare yet significant block-related complications. Despite these limitations, our study is the most up-to-date and comprehensive meta-analysis.

Conclusion

Our review of nine RCTs revealed that patients undergoing breast cancer surgeries in ESPB group significantly have less postoperative opioid consumption and low demand of postoperative use of analgesia and took more time to use their first postoperative analgesia than those in SAPB group; however, this difference remained clinically unimportant. The postoperative pain scores, the incidence of nausea and vomiting, and the satisfaction score among both groups were comparable; hence, current evidence cannot define the relative superiority of one block over the other. Our findings warrant further research with standardized methodologies and a longer duration of analgesic efficacy assessment to yield robust evidence for better clinical applications.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s44158-024-00218-7.

Supplementary Material 1. Supplementary Material 2. Supplementary Material 3.

Acknowledgements

A Large language model, ChatGPT-4, was utilized for assistance with grammatical corrections and language refinement during the preparation of this manuscript.

Clinical trial number

Not applicable

Authors' contributions

S.S, N.M.A and Q.M made substantial contributions to the conception and design of the study, data acquisition, and analysis, and drafted the initial manuscript. U.S.S.B, M.K, S.K, PD, R.I, and A.N made substantial contributions to the data interpretation, extraction and critical revision of the manuscript. M.A.K, S.S and R.B.H made significant contributions to designing tables, figures and data interpretation, particularly in the context of clinical aspects, and provided critical revisions. S.S, S.A, M.H.S, H.M, and A.F assisted in data collection and analysis, contributing to the acquisition of essential data for the study. All authors read and approved the final manuscript.

Funding

The authors received no funding for this research.

Data availability

Data is provided within the manuscript or supplementary information files.

Declarations

Ethics approval and consent to participate Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan. ²Dow University of Health Sciences, Karachi, Pakistan. ³Bukovinian State Medical University, Chernivtsi, Ukraine. ⁴Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan. ⁵Allama Iqbal Medical College, Lahore, Pakistan. ⁶Services Institute of Medical Sciences(SIMS), Lahore, Pakistan. ⁷Jinnah Hospital, Lahore, Pakistan. ⁸Rawalpindi Medical University, Rawalpindi, Pakistan. Received: 18 August 2024 Accepted: 5 December 2024 Published online: 18 December 2024

References

- AI –Gaithy ZK, Yaghmoor BE, Koumu MI, Alshehri KA, Saqah AA, Alshehri HZ. Trends of mastectomy and breast-conserving surgery and related factors in female breast cancer patients treated at King Abdulaziz University Hospital, Jeddah, Saudi Arabia, 2009–2017: A retrospective cohort study. Ann Med Surg. 2019;41:47–52.
- Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A (2021) Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers 13(17):4287
- Ephrem Tadele Sedeta, Bilain Jobre, and Boris Avezbakiyev. Breast cancer: global patterns of incidence, mortality, and trends. | Journal of Clinical Oncology. Available from: https://ascopubs.org/doi/https://doi.org/10. 1200/JCO.2023.41.16_suppl.10528. Cited 2024 Jun 5.
- Wang L, Guyatt GH, Kennedy SA, Romerosa B, Kwon HY, Kaushal A et al (2016) Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. CMAJ Can Med Assoc J 188(14):E352–E361
- Chronic pain in female breast cancer survivors prevalence, characteristics and contributing factors: a cross-sectional pilot study | BMC Women's Health | Full Text. Available from: https://bmcwomenshealth.biomedcentral.com/articles/https://doi.org/10.1186/s12905-023-02766-6. Cited 2024 Jun 5.
- Doan LV, Yoon J, Chun J, Perez R, Wang J. Pain associated with breast cancer: etiologies and therapies. Front Pain Res. 2023;4. Available from: https://www.frontiersin.org/articles/https://doi.org/10.3389/fpain.2023. 1182488. Cited 2024 Jun 5
- Ellis A, Bennett DLH (2013) Neuroinflammation and the generation of neuropathic pain. Br J Anaesth 111(1):26–37
- Satija A, Ahmed SM, Gupta R, Ahmed A, Rana SPS, Singh SP et al (2014) Breast cancer pain management - a review of current & novel therapies. Indian J Med Res 139(2):216–225
- Brenin DR, Dietz JR, Baima J, Cheng G, Froman J, Laronga C et al (2020) Pain management in breast surgery: recommendations of a multidisciplinary expert panel-The American Society of Breast Surgeons. Ann Surg Oncol 27(12):4588–4602
- Chin KJ, Pawa A, Forero M, Adhikary S (2019) Ultrasound-guided fascial plane blocks of the thorax: pectoral I and II, serratus anterior plane, and erector spinae plane blocks. Adv Anesth 37:187–205
- Southgate SJ, River GF, Herbst MK. Ultrasound-guided serratus anterior blocks. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: http://www.ncbi.nlm.nih.gov/books/NBK538476/. Cited 2024 Jun 5.
- 12. Krishnan S, Cascella M. Erector spinae plane block. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: http://www.ncbi. nlm.nih.gov/books/NBK545305/. Cited 2024 Jun 5
- Sia CJY, Wee S, Au-Yong APS, Lie SA, Tan WJ, Foo FJ et al (2024) Analgesia efficacy of erector spinae plane block in laparoscopic abdominal surgeries: a systemic review and meta-analysis. Int J Surg Lond Engl 110(7):4393–4401
- Muthu S, Viswanathan VK, Annamalai S, Thabrez M. Bilateral erector spinae plane block for postoperative pain relief in lumbar spine surgery: a PRISMA-compliant updated systematic review & meta-analysis. World Neurosurgery: X . 2024;23:100360. Available from: https://pmc.ncbi.nlm. nih.gov/articles/PMC10950749/. Cited 2024 Oct 29.
- Patel N, Fayed M, Maroun W, Milad H, Adlaka K, Schultz L et al (2024) Effectiveness of erector spinae plane block as perioperative analgesia in midline sternotomies: a systematic review and meta-analysis of randomized controlled trials. Ann Card Anaesth 27(3):193–201
- Leong RW, Tan ESJ, Wong SN, Tan KH, Liu CW (2021) Efficacy of erector spinae plane block for analgesia in breast surgery: a systematic review and meta-analysis. Anaesthesia 76(3):404–413
- Li ZH, Hong WJ, Guo XL, Li XR, Jiang XY, Jiang Y et al (2023) Serratus plane block in breast cancer surgery: a systematic review and meta-analysis. Clin Breast Cancer 23(1):e1-13

- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29:n71
- Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14(1):135
- Luo D, Wan X, Liu J, Tong T (2018) Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res 27(6):1785–1805
- 21. PlotDigitizer: a tool for extracting data from graph images. Retrieved from https://plotdigitizer.com/
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 28(366):I4898
- 23. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011 Apr;64(4):383–94.
- 24. Oregon Pain Guidance. Opioid conversion calculator for morphine equivalents. Available from: https://www.oregonpainguidance.org/opioi dmedcalculator/. Cited 2024 Jun 9
- Cheung BWY, Cartier LL, Russlie HQ, Sawchuk RJ (2005) The application of sample pooling methods for determining AUC, AUMC and mean residence times in pharmacokinetic studies. Fundam Clin Pharmacol 19(3):347–354
- 26. The Hartung-Knapp-Sidik-Jonkman method for random effects metaanalysis is straightforward and considerably outperforms the standard DerSimonian-Laird method | BMC Medical Research Methodology | Full Text. Available from: https://bmcmedresmethodol.biomedcentral.com/ articles/https://doi.org/10.1186/1471-2288-14-25. Cited 2024 Jun 9.
- Cook CE (2008) Clinimetrics corner: the minimal clinically important change score (MCID): a necessary pretense. J Man Manip Ther 16(4):E82-83
- 28. Muhammad QUA, Sohail MA, Azam NM, Bashir HH, Islam H, Ijaz R et al (2024) Analgesic efficacy and safety of erector spinae versus serratus anterior plane block in thoracic surgery: a systematic review and metaanalysis of randomized controlled trials. J Anesth Analg Crit Care 4(1):3
- Chapter 10: Analysing data and undertaking meta-analyses. Available from: https://training.cochrane.org/handbook/current/chapter-10. Cited 2024 Jun 9.
- 30. Eldemrdash AM, Abdelzaam ESM (2019) By ultrasonic-guided erector spinae block, thoracic paravertebral block versus serratus anterior plane block by articaine with adrenaline during breast surgery with general anesthesia: a comparative study of analgesic effect post-operatively: double blind randomized, controlled trial. Open J Anesthesiol 09(04):68
- Elsabeeny WY, Shehab NN, Wadod MA, Elkady MA (2020) Perioperative analgesic modalities for breast cancer surgeries: a prospective randomized controlled trial. J Pain Res 13:2885–2894
- Wang HJ, Liu Y, Ge WW, Bian LD, Pu LF, Jiang Y et al (2019) Comparison of ultrasound-guided serratus anterior plane block and erector spinae plane block perioperatively in radical mastectomy. Zhonghua Yi Xue Za Zhi 99(23):1809–1813
- 33. Jiang CW, Liu F, Zhou Q, Deng W (2021) Comparison of rhomboid intercostal nerve block, erector spinae plane block and serratus plane block on analgesia for modified radical mastectomy: A prospective randomised controlled trial. Int J Clin Pract 75(10):e14539
- 34. Nyima T, Palta S, Saroa R, Kaushik R, Gombar S (2023) Ultrasound-guided erector spinae plane block compared to serratus anterior muscle block for postoperative analgesia in modified radical mastectomy surgeries: a randomized control trial. Saudi J Anaesth 17(3):311–317
- 35. Ahuja D, Kumar V, Gupta N, Bharati SJ, Garg R, Mishra S et al (2022) Comparison of the efficacy of ultrasoundguided serratus anterior plane block versus erector spinae plane block for postoperative analgesia after modified radical mastectomy: a randomised controlled trial. Turk J Anaesthesiol Reanim 50(6):435–442
- Abd Elmohsen Bedewy A, Mohamed MS, Sultan HM, Khalil MS. Comparison between erector spinae plane block versus serratus anterior plane block regarding analgesia and stress response after modified radical mastectomy: randomized controlled trial. Anesthesiol Pain Med. 2024 Apr;14(2):e142189.

- Abd Elmohsen Bedewy, A., Mohamed, M. S., Sultan, H. M., & Khalil, M. S. (2024). Comparison between erector spinae plane block versus serratus anterior plane block regarding analgesia and stress response after modified radical mastectomy: randomized controlled trial. *Anesthesiology and pain medicine*, 14(2), e142189. https://doi.org/10.5812/aapm-142189
- Shrivastava A, Gour V, Chandrakant, Hingwe S. To compare the effectiveness of erector spinae plane block with serratus anterior plane block for breast surgery-a comparative study. Journal of cardiovascular disease research, 2021, 12(6), 1326-1330. https://doi.org/10.31838/jcdr.2021.12. 06.185
- Pawa A, King C, Thang C, White L (2023) Erector spinae plane block: the ultimate 'plan A' block? Br J Anaesth 130(5):497–502
- Kietaibl S, Ferrandis R, Godier A, Llau J, Lobo C, Macfarlane AJ et al (2022) Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ ESRA guidelines. Eur J Anaesthesiol 39(2):100–132
- Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg Anesth Pain Med. 2018;43(3):263–309.
- Konishi T, Fujiogi M, Shigemi D, Matsui H, Fushimi K, Tanabe M et al (2022) Risk factors for postoperative bleeding following breast cancer surgery: a nationwide database study of 477,108 cases in Japan. World J Surg 46(12):3062–3071
- De Cassai A, Geraldini F, Carere A, Sergi M, Munari M (2021) complications rate estimation after thoracic erector spinae plane block. J Cardiothorac Vasc Anesth 35(10):3142–3143
- 44. Luff D, Moosa F, Sadavarte N, Pinnamaneni N, Bedforth N (2021) 136 Which blocks can you do? An assessment of anaesthetic trainee confidence performing common peripheral nerve blocks. Reg Anesth Amp Pain Med 70(Suppl 1):A71
- 45. White LD, Riley B, Davis K, Thang C, Mitchell A, Abi-fares C, et al. Safety of continuous erector spinae catheters in chest trauma: a retrospective cohort study. Anesth Analg. 2021; Available from: https://journals.lww. com/https://doi.org/10.1213/ANE.000000000005730. Cited 2024 Sep 29.
- 46. Moon S, Lee J, Kim H, Kim J, Kim J, Kim S (2020) Comparison of the intraoperative analgesic efficacy between ultrasound-guided deep and superficial serratus anterior plane block during video-assisted thoracoscopic lobectomy: a prospective randomized clinical trial. Medicine (Baltimore) 99(47):e23214
- Piracha MM, Thorp SL, Puttanniah V, Gulati A (2017) "A tale of two planes": deep versus superficial serratus plane block for postmastectomy pain syndrome. Reg Anesth Pain Med 42(2):259–262
- Meng J, Zhao HY, Zhuo XJ, Shen QH (2023) Postoperative analgesic effects of serratus anterior plane block for thoracic and breast surgery: a meta-analysis of randomized controlled trials. Pain Physician 26(2):E51-62

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.